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Executive summary
Rapid demographic, sociocultural, and economic
transitions are driving increases in the risk and prevalence
of diabetes and other non-communicable diseases
(NCDs) in sub-Saharan Africa. The impacts of these
transitions and their health and economic consequences
are evident. Whereas, in 1990, the leading causes of death
in sub-Saharan Africa were HIV/AIDS, lower respiratory
infections, diarrhoeal diseases, malaria, and vaccinepreventable diseases in children, in more recent years,
cardiovascular diseases and their risk factors are replacing
infectious diseases as the leading causes of death in this
region, and rates of increase of cardiovascular risk factors
are predicted to be greater in sub-Saharan Africa than in
other parts of the world. Thus, sub-Saharan Africa—
which contains a high proportion of the world’s least
developed countries—will face the multifaceted challenge
of dealing with a high burden of infectious diseases and
diseases of poverty, while also addressing the increasing
burden of cardiovascular disease and its risk factors. At
present, many of the health systems in sub-Saharan
Africa struggle to cope with infectious diseases. Meeting
the goals of the UN high-level meeting on NCDs (to
reduce premature mortality from NCDs by 25% by 2025)
and Sustainable Development Goals (SDGs; to reduce
premature mortality from NCDs by a third by 2030)
requires a coordinated approach within countries, which
starts with a firm consideration of disease burden, needs,
and priorities.
Diabetes is an exemplar risk factor of cardiovascular
disease in that its prevalence tracks the transitions that
lead to the precursors of cardiovascular disease—namely
obesity and overweight. The prevalence of diabetes is
increasing rapidly in sub-Saharan Africa.1 If left
untreated, diabetes leads to a plethora of complications,
both microvascular and macrovascular, that affect
multiple physiological systems. Additionally, diabetes is
closely associated with other cardiovascular risk factors,
including hypertension and hypercholesterolaemia,
which interact to exacerbate the risk of adverse outcomes.
Thus, diabetes requires an interconnected, broad-based
health system for its effective management. Improving

the processes of care for people with diabetes should lead
to improvement of health systems for many other
conditions. If left unchecked, however, the adverse
outcomes of diabetes and other cardiovascular risk
factors could overwhelm health systems in sub-Saharan
Africa and leave many of those affected with substantial
morbidity and mortality. The interaction of diabetes with
infectious diseases further increases the burden of
illness on resource-constrained health systems.
The Lancet Diabetes & Endocrinology Commission on
Diabetes in sub-Saharan Africa was formed to ascertain
the current burden of diabetes and its risk factors and
outcomes in the region, to assess challenges faced by
health systems in dealing with this burden, and to
suggest potential solutions. We present the key messages
of the Commission below and also suggest operational
targets (panel 1) to help countries at all stages of
development to transition to a state whereby the UN and
SDG targets on NCDs can be achieved, if not surpassed.

Key message 1: the true burden of diabetes, other
cardiovascular risk factors, and macrovascular and
microvascular complications in sub-Saharan Africa is
unknown
Estimates from those countries in which high-quality
data are available suggest that the increase in the
prevalence of diabetes, other cardiovascular risk factors,
and adverse outcomes is large and is expected to further
increase. However, most countries do not have data or
data collection systems that are sufficiently reliable to
enable mounting of a commensurate health-system
response. To plan such a response requires high-quality,
population-representative data on both current burdens
and associated demographic factors and that systems for
longitudinal data collection be put in place. It is also
imperative to ascertain which tests and cutoffs for
hyperglycaemia are most appropriate for use in defining
diabetes in populations in sub-Saharan Africa to prevent
overtreatment or undertreatment.
Knowledge about the burden of type 1 diabetes is
particularly important given that this condition is fatal in
the absence of relatively inexpensive treatment.
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Key message 2: diabetes and its consequences are costly
to patients and economies
We estimate that, in 2015, the overall cost of diabetes in
sub-Saharan Africa was US$19·45 billion or 1·2% of
cumulative gross domestic product (GDP). Around
$10·81 billion (55·6%) of this cost arose from direct costs,
which included expenditure on diabetes treatment (eg,
medication, hospital stays, and treatment of
complications), with out-of-pocket expenditure likely to
exceed 50% of the overall health expenditure in many
countries. We estimate that the total cost will increase to
between $35·33 billion (1·1% of GDP) and $59·32 billion
(1·8% of GDP) by 2030. Putting in place systems to
prevent, detect, and manage hyperglycaemia and its
consequences is therefore warranted from a health
economics perspective.

Key message 3: health systems in countries in
sub-Saharan Africa are unable to cope with the current
burden of diabetes and its complications
By use of information from WHO Service Availability
Readiness Assessment surveys and World Bank Service
Delivery Indicator surveys and the local knowledge of
Commissioners, we found inadequacies at all levels of
the health system required to provide adequate
management for diabetes and its associated risk factors
and sequelae. We found inadequate availability of
simple equipment for diagnosis and monitoring, a lack
of sufficiently knowledgable health-care providers,
insufficient availability of treatments, a dearth of locally
appropriate guidelines, and few disease registries.
These inadequacies result in a substantial dropoff of
patients along the diabetes care cascade, with many
patients going undiagnosed and with those who are
diagnosed not receiving the advice and drugs they need.
We also noted scarce facilities to manage the
microvascular and macro
vascular complications of
diabetes. Additionally, despite calls for adding the care
of diabetes and other cardiovascular risk factors onto
existing infectious disease programmes (such as those
for HIV), we found little evidence that such combined
programmes are successful at improving outcomes.

Key message 4: scarce health-care resources should be
focused on the management of diabetes and other risk
factors to prevent complications
The management of diabetes and its risk factors is
reasonably simple and inexpensive. Treating compli
cations, however, is costly, requiring providers with a
high level of skill and specialised equipment.
Prevention of complications is therefore crucial. To
allow effective prevention of complications, decentralisation of care—from experts who work in
hospitals to community health workers and other nonclinical providers who work in the primary care system
and deliver home-based screening and care—needs to
be accelerated. Simple and effective information

technology solutions should be used to enable more
locally delivered care. An additional consideration is
whether it is more beneficial to treat each risk factor
associated with diabetes to predefined targets, or to
consider risk factors collectively and aim to reduce
overall risk. For both the prevention of macrovascular
and microvascular risk factors, our analyses suggest it
will be more effective and cost-effective to consider risk
factors as a whole, and use benefit-based tailored
treatment, rather than to treat each individual
cardiovascular risk factor to a target.
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Panel 1: Priorities and targets for diabetes care to 2030
When health resources are severely limited, difficult choices must often be made in the
face of competing priorities. Our review of the challenges involved makes it clear that
models of diabetes care for use in high-income countries are neither appropriate nor
affordable in low-income or middle-income countries. We advocate the pursuit of a
utilitarian approach to the provision of diabetes care in most sub-Saharan African
settings, involving widely available inexpensive treatments for prevention of
complications alongside strong public health measures to prevent increases in the
prevalence of obesity and diabetes. Investment in preventing the consequences of
diabetes will prevent the necessity of investing in wider-scale availability of expensive
treatments to manage diabetes complications. Rigorous health-systems research and
implementation science2 to accompany the introduction of new treatments or
management strategies are key to ensuring that solutions are both fitting to a local
environment and that results obtained can be of use to other countries. Funding for this
type of research is urgently required.
We therefore propose a hierarchy-of-needs model of care on the basis of strategies
known to work in other settings. This hierarchy is based on the Commissioners’
experience in both clinical care and health-system improvement and our review of the
literature during the process of this Commission. The principles of this hierarchy are
straightforward: each intervention should be evidence-based, effective, accessible,
integrated, and affordable. Of key importance, the Commission calls for services for
provision of care and diagnostics for diabetes, its risk factors, and its complications to be
fully integrated to minimise the indirect costs to the patient of having to attend multiple
clinic appointments.
The prerequisites for introduction of treatment modalities or therapies are education and
structure. The aims of education are achieved at personal, community, and
health-care-provider levels. At a personal level, the aim is to make the patient an active,
informed partner in their own therapy rather than a passive recipient. At the community
level, the aim is to increase understanding and awareness of diabetes and eliminate
prejudice. Education of medical personnel is needed to raise awareness of the disease and
the simplicity of its treatment, and also to counterbalance marketing and medical
education campaigns by the pharmaceutical industry, which are typically slanted towards
use of more expensive, patented forms of treatment. An appropriate structure for
health-care delivery, which is embedded in the health system, is equally essential.
We have considered necessary care needs in terms of the level of service-provision
development in countries. We progress from care that we consider to be essential (which we
refer to as level one care) and recommend should be available in 100% of countries by 2020;
to level two care, which we consider should be the next step when level one care is achieved
and should be available in 75% of countries by 2020 and in 100% of countries by 2025; and
then to level three care, which should be considered once other targets have been achieved.
We recommend that level three care should be present in 50% of countries by 2020, 75% of
countries by 2025, and 100% of countries by 2030 (table 1).
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Key message 5: more evidence is needed about the
benefits and risks (to individuals and health systems) of
screening before programmes are rolled out across
sub-Saharan Africa
The benefits of screening, especially in people who are
deemed to be at high risk, seem obvious: earlier detection
and management of diabetes and its risk factors and
prevention of costly complications. However, as of yet,

there is little evidence—even from high-income countries,
where studies have been done—that screening
programmes are effective at reducing adverse outcomes.
Additionally, the thresholds for diagnosing diabetes (ie, the
level of glycaemia that is associated with the risk of adverse
outcomes in the long term) and the best test to use are not
defined for populations in sub-Saharan Africa. Hence, any
screening programme that is started should only be done

Level one

Level two

Level three

Target

100% availability or uptake by 2020

75% availability or uptake by 2020; 100% availability or
uptake by 2025

50% availability or uptake by 2020; 75% availability or
uptake by 2025; 100% availability or uptake by 2030

Medications
and equipment

Availability of treatments for hyperglycaemia
(metformin, sulfonylureas, and short-acting and
intermediate-acting human insulin) at health-care
facilities at all levels (including community facilities and
pharmacies)
Availability of essential medicines for hypertension at all
health facilities (including community facilities and
pharmacies)
Availability of angiotensin-converting enzyme inhibitors
to treat diabetic nephropathy and prevent microvascular
disease at all health-care facilities (including community
facilities and pharmacies)
Availability of off-patent medicines to treat
hyperlipidaemia at all health-care facilities
Availability of blood glucose and ketone sticks at all health
facilities (including community health facilities)
Availability of working sphygmomanometers of
appropriate cuff size at all health facilities
(including community health facilities)

Availability of essential medicines for secondary
prevention of cardiovascular disease at all health-care
facilities (including community facilities and
pharmacies)
Access to home urine glucose sticks for patients to
assess glycosuria at least three times per week
Availability of affordable and sustainable technologies
for self-monitoring of blood glucose in those people
with diabetes using insulin
Availability of affordable or portable digital photography
equipment for taking and transmitting retinal images
for remote interpretation
Availability of affordable or portable equipment for
retinal image acquisition, image transfer, and image
grading
Provision of laser equipment for treatment of diabetic
retinopathy

Availability of affordable and sustainable selfmonitoring of blood glucose equipment for all patients
with diabetes, and availability of glucose strips for
testing at least three times per day on 3 days per week
Therapeutic options for erectile dysfunction
Orthotics for people with foot deformities to prevent
ulceration
Availability of intravitreal anti-VEGF drugs to treat
diabetic retinopathy

Service delivery

Availability of services to provide education and
counselling for patients with diabetes or gestational
diabetes at all health-care facilities
Availability of screening for gestational diabetes with
2013 WHO criteria3 for high-risk women attending
antenatal services at all health-care facilities
Availability of regular (3 monthly) follow-up for diabetes
and associated conditions via community health
workers or primary care facilities
Availability of services to deliver regular supplies of
medicines within patients’ local areas
Clearly delineated referral pathways between
community, secondary, and specialised or tertiary care
centres

Availability of laboratory tests for fasting blood glucose,
HbA1C, and renal function at all secondary and tertiary
referral centres
Availability of services to screen for diabetic retinopathy,
integrated into general services for diabetes care
Access to tertiary care facilities for treatment of cataracts
and retinopathy
Availability of community support groups
Availability of annual review at a specialist diabetes clinic
(with facilities for annual HbA1C measurement, screening
for complications, assessment of proteinuria with urine
strips, measurement of serum creatinine, retinal
photography for people at high risk of retinopathy, and
monofilament or tuning fork testing for peripheral
neuropathy) for all patients with diabetes

Access to secondary or tertiary care facilities for cataract
surgery and treatment of diabetic retinopathy with laser
and intravitreal anti-VEGF drugs
Access to tertiary care facilities for vitreoretinal surgery
to treat advanced diabetic retinopathy
Wide-scale access to dialysis and renal transplantation,
vascular surgery for peripheral vascular disease, and
percutaneous coronary intervention and coronary artery
bypass grafting at tertiary care facilities
Rehabilitation programmes and prostheses for people
after a stroke or amputation

Information

At the diabetes clinic level, ensure availability of simple,
future-proof diabetes registries to allow documentation of
diabetes control, medications, and complications, and
triggering of recall
Availability of information technology to allow remote
interpretation of digital retinal photos taken in clinics in
which no expertise in interpretation is available
Availability of basic diabetes education, including
information about prevention and detection of
complications, that is culturally appropriate, provided in
a local language, and understandable to patients and
their relatives
Widespread availability of information about and
campaigns to promote a healthy lifestyle that is tailored
to the local population, culturally appropriate, and
delivered through media platforms that are widely used
by the local population
Availability of a basic cardiovascular risk calculator at
each primary health-care facility

Fully integrated, cloud-based patient information
Availability of electronic links between specialist
systems for storing diabetes-relevant information along
diabetes clinics and primary care providers, allowing
with all other key records of diagnoses and treatment
updates on test results, prescription modification, and
follow-up and referral information
Availability of a cloud-based storage system for storage
of and access to electronic diabetes records by primary
and secondary providers
Availability of a mobile phone alert system to
communicate results and changes to treatments to
patients and to alert patients to follow-up appointments
Availability of equipment allowing yearly training
updates for primary health-care workers and others
providing diabetes care, to be delivered by distance
learning

(Table 1 continues on next page)
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Level one

Level two

Level three

(Continued from previous page)
Workforce

Training (with ongoing regular support and mentoring)
of enough community health-care workers (appropriate
to current and projected burden) in each region to aid
case finding and provide adherence support and
preventive care and information
Training of health-care workers who provide antenatal
care to recognise women at high risk of gestational
diabetes and refer them to antenatal services offering
screening and treatment
Ensure all primary care providers are trained to recognise
and treat hyperglycaemia
Ensure all primary care providers are trained to screen for
and treat associated cardiovascular risk factors in
patients with diabetes and recognise when to refer a
patient for more specialised care
Provision of training on recognition and referral of
diabetic retinopathy cases to the existing eye-care
workforce

Trained diabetes educators in each district to support
community health workers and people with diabetes
Training for all health-care providers to recognise the
symptoms of diabetes and its complications, as well as the
means of diagnosis
Ensure availability of one paediatric and one adult
endocrinologist at each tertiary care centre in each
country
Provide training on diabetes to traditional healers to
allow them to recognise the symptoms and refer
potential sufferers to medical care
Ensure availability of appropriately trained retinal
photographers and retinal image graders
Ensure availability of one or more ophthalmologist
trained to deliver treatment for diabetic retinopathy in
each tertiary care centre in each country

Specialist diabetes workforce expanded to enable one
annual visit for each patient with a fully trained
diabetologist
Availability of multidisciplinary teams for the
management of hyperglycaemia in pregnancy

Financing

Ensure all necessary care for diabetes and associated
cardiovascular risk factors is made freely available to
those living below the World Bank 20154 defined poverty
line of US$1·90 per day

Ensure all essential care for diabetes and associated
cardiovascular risk factors (including access to screening,
regular follow-up [including blood tests], access to
medicines for primary and secondary prevention,
follow-up by a specialist once per year, and detection of
microvascular complications) is covered by universal
health coverage schemes such that no patient has to pay
direct costs of care out of pocket

Ensure availability of detection and treatment facilities
for macrovascular and microvascular complications of
diabetes, with no patient suffering catastrophic
expenditure for accessing care

Knowledge

Ascertain most appropriate method (in terms of
predicting future complications) for diagnosing diabetes
in sub-Saharan Africa
Ascertain most appropriate method (in terms of ability
to predict maternal and neonatal complications) of
diagnosing gestational diabetes
Ascertain most appropriate method for retinal image
acquisition, image grading, and targeted case detection
in low-resource environments

Obtain reliable in-country estimates (for example, with
the STEPwise approach to surveillance method5) from
adequately sized samples of the burdens of obesity,
diabetes, and other cardiovascular risk factors
Obtain reliable in-country estimates from adequately
sized samples of the burden of gestational diabetes
Assess ability of country health systems to provide care
for in-country burden of patients with diabetes

Development of a sub-Saharan African NCD research
group and plan that includes a strategy for collaboration
and data sharing
Ensure that research of diabetes and other NCDs in subSaharan Africa (including clinical trials) is led by
researchers residing in sub-Saharan Africa

Leadership and
governance

Maintain a dedicated team within the Ministry of Health
with responsibility for overseeing country-wide, phased
rollout of diabetes care
Appoint a dedicated government minister with
responsibility for developing and overseeing
government policies to prevent obesity and overweight
and encourage healthy lifestyles
Maintain a dedicated team within the Ministry of Health
with responsibility for ensuring wide-scale rollout of
public health messages and policies to prevent and
reverse obesity and overweight
WHO to assemble working groups (consisting of
practitioners, health policy makers, laboratory and
diagnostic experts, device manufacturers, and health
information technology companies) to produce a list of
essential diagnostics and diagnostic equipment for NCDs
and to create guidelines on technical standards

Integrate teams within ministries that deal with diabetes ··
care and prevention into wider NCD teams
Introduce taxation policies for sugar-sweetened
beverages and policies to ensure all new urban
developments are walkable
Integration of members of teams within ministries that
deal with diabetes care and prevention into teams
addressing universal health coverage strategies
WHO to assemble a working group to advise on
information technology solutions for integrated patient
records, which include diabetes and other NCD registries,
and to explore future-proof and interoperable cloudbased solutions that can be used in LMICs

VEGF=vascular endothelial growth factor. NCD=non-communicable disease. LMICs=low-income and middle-income countries.

Table 1: Three levels of operational targets to 2030

as part of a rigorous longitudinal outcomes study that also
compares different tests for diagnosis of hyperglycaemia.

Introduction
Sub-Saharan Africa is experiencing a rapid increase in
the prevalence of non-communicable diseases (NCDs).
Although, in 2015, Africa was the only continent in the
world where morbidity and mortality from infectious

diseases still surpassed that from NCDs, this balance will
soon change as the region experiences the full impact of
the increase in NCDs.6
Rapid demographic (growing and ageing population),
sociocultural (lifestyle changes and eating habits), and
economic (higher income, urbanisation, changing food
availability, and evolving lifestyle and work practices)
transitions7,8 are driving increases in the risk factors and
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prevalence of diabetes and other risk factors of
cardiovascular disease. In sub-Saharan Africa,
between 1980 and 2015, the number of people older than
20 years with a BMI of greater than 25 kg/m² increased
from 28 million to 127 million, while the disease burden
attributed to diabetes, as measured by disability-adjusted
life-years (DALYs), increased by 88%.9 More than 90% of
diabetes cases in sub-Saharan Africa are type 2 diabetes,
suggesting that modifiable risk factors are major
contributors to the burden of disease.10
Against this backdrop of dramatic statistics is the
uncomfortable reality that most estimates for diabetes,
other cardiovascular disease risk factors, and cardio
vascular disease burden per se in countries in subSaharan Africa have been modelled from generally
poor-quality evidence using methods of defining diabetes
that have been developed in high-income countries
(HICs), often with European-origin populations. In the
case of diabetes, a 2016 study11 found that nationally
representative empirical biomarker data on diabetes
diagnosis were not available from 21 of countries in subSaharan Africa. So, although there is reasonable evidence
that diabetes and other cardiovascular risk factors are
increasing, the certainty of the situation is far from clear.
Most (34 [71%] of 48 countries) of the world’s leastdeveloped countries are in sub-Saharan Africa.12 Thus,
although the focus of development aid and research
funding has so far been on infectious diseases,13,14 many
countries are still struggling to develop health systems to
cope with the existing infectious disease burden, which is
much better delineated than that of cardiovascular disease
and its risk factors. It therefore seems an impossible task
to ask these countries—as has been requested by the
Sustainable Development Goals (SDGs) and the UN
high-level meeting on NCDs15—to respond to an as yet
not accurately quantified burden of cardiovascular disease
risk factors, using methods not yet proven to be effective
in the region, and with little funding.
Driven by this recognition, a group of academics, policy
makers, and clinicians met at the Rockefeller Foundation

Prevalence (%)
1980

Percentage change Number
for 1980–2014
(millions)

2014

1980

Percentage change
for 1980–2014

2014

African region

3·1%

7·1%

129·0%

4

25

525·0%

Region of the Americas

5·0%

8·3%

66·0%

18

62

244·4%

Eastern Mediterranean
region

5·9%

13·7%

132·2%

6

43

616·7%

European region

5·3%

7·3%

37·7%

33

64

93·9%

Southeast Asia region

4·1%

8·6%

109·8%

17

96

464·7%

Western Pacific region

4·4%

8·4%

90·9%

29

131

351·7%

Worldwide total

4·7%

8·5%

80·9%

108

422

290·7%

Data from reference 13.

Table 2: Estimated prevalence of diabetes and number of adults aged 18 years or older with diabetes
in 1980 and 2014, by WHO region
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Bellagio Center in Italy in March, 2015, to discuss the
state of play and potential routes forward. We centred our
discussions on diabetes—a preventable cardiovascular
disease risk factor—because of its multi-system
interactions and adverse outcomes and because broad
improvements in health-care systems are needed for its
management. We formed The Lancet Diabetes &
Endocrinology Commission on Diabetes in sub-Saharan
Africa. After the meeting in Bellagio, we organised
ourselves into working groups to look at both clinical and
health-system elements involved in diabetes and diabetes
care in sub-Saharan Africa. We met again at the
World Diabetes Congress in Vancouver, Canada, in
November, 2015, to discuss progress. The final
Commission meeting was held at the Harvard Medical
School Center for Global Health Delivery, Dubai, in
February, 2016, to report results, discuss areas in which
we had found equipoise, agree on the best approaches to
advise in these areas, and structure the report.
Here, we present the findings of the Commission,
including discussions of burden, and clinical, economic,
and broader health systems, to inform the development
of an effective response to the increasing burden of
diabetes, other cardiovascular disease risk factors, and
their adverse consequences. The methods used in
sections of the report that involved novel research can be
found in detail in the appendix 1. The narrative sections
of the report were informed by extensive reviews of the
literature and the knowledge and opinions of the
Commissioners.

Burden of diabetes in sub-Saharan Africa
Globally, according to the NCD Risk Factor Collaboration
(NCD-RisC), the number of adults with diabetes
increased from 108 million (a prevalence of 4·7%) in 1980
to 422 million (8·5%) in 2014—an increase in prevalence
of 80·9%.16 Notably, diabetes prevalence in the WHO
African region increased by 129·0% (from 3·1% in 1980
to 7·1% in 2014; table 2). This increase is second only to
the WHO eastern Mediterranean region, in which the
prevalence of diabetes increased by 132·2% (from 5·9%
in 1980 to 13·7% in 2014; table 2).
Unfortunately, the various estimates of diabetes
prevalence in sub-Saharan Africa have used different
methodologies, all of which have limitations (panel 2).
Hence, no clear data exist on the prevalence of diabetes
in this region, which is important for planning an
adequate health-systems response. In addition to WHO
and NCD-RisC, other well cited estimates come from the
International Diabetes Federation (IDF)25 and the Global
Burden of Disease (GBD) group at the Institute for
Health Metrics and Evaluation,9 which has produced
estimates of deaths and DALYs due to diabetes. However,
despite differences in methodologies, all estimates point
to an increasing burden of diabetes in sub-Saharan
Africa. Notwithstanding the limitations of the methods
used to estimate diabetes prevalence (panel 2), the
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estimates used in this report are from NCD-RisC,16
unless otherwise stated. We have chosen these estimates
because they have been adopted by WHO and are
therefore likely to gain global credibility.
The increasing impact of diabetes in sub-Saharan
Africa is reflected in results from the 2015 GBD study,9
which estimated that diabetes in the region caused an
average of 145 189 deaths and 5 556 560 DALYs; DALYs
attributable to diabetes increased by 88% between 1990
and 2010.9 Inevitably, there is considerable imprecision
in such estimates and other groups have produced
different figures. For example, the IDF estimated that,
in 2015, around 321 000 deaths in sub-Saharan Africa
were attributable to diabetes, and that 79% of those
deaths occurred in people aged 60 years or younger—a
proportion higher than in any other region in the world.25

Type 2 diabetes in sub-Saharan Africa
Overview

As in other parts of the world, more than 90% of people
living with diabetes in sub-Saharan Africa have type 2
diabetes,10,26 which is typically associated with increasing
age and overweight or obesity. We refer to type 2 diabetes
simply as diabetes throughout this report, and specify
type when referring to other types of diabetes.

Drivers of type 2 diabetes
Overweight and obesity
Traditionally, lifestyle factors leading to overweight and
obesity, and then to diabetes, have been considered
modifiable. However, it is now increasingly acknowledged
that, at least at the individual level, lifestyle drivers of
diabetes are difficult to modify; individuals have far less
agency than was previously thought.8,27 Additionally,
genetic predisposition to overweight, obesity, and
diabetes—once thought to be relatively stable over
geological timeframes—is now known to be more
modifiable in the short term than previously considered,
possibly via intergenerational epigenetic changes (see
panel 3 for a discussion of genetic drivers of diabetes in
sub-Saharan Africa). Although susceptibility to diabetes
and its risk factors varies, the condition is largely
avoidable with appropriate interventions.
Although not all people with diabetes in sub-Saharan
Africa are overweight or obese by western standards, a
rapid increase in the prevalence of overweight and
obesity is undoubtedly a major driver of the increasing
prevalence of type 2 diabetes in the region.9,16 The
contribution of overweight and obesity to the variance of
the prevalence of diabetes in sub-Saharan Africa is an as
of yet unanswered question; some studies37–39 suggest
that African populations might develop diabetes at lower
body mass than people of European origin, and other
studies in different settings40,41 have suggested that, for
the same level of obesity, African populations are at lower
risk for diabetes than their western counterparts. However,
high-quality, convincing evidence is scarce.

Globally, overweight and obesity are traditionally
considered conditions of urban rather than rural
populations, although this situation is now in
transition. In HICs, overweight and obesity are seen
more in rural populations than in urban populations.21,41
Few high-quality longitudinal studies have been done
in Africa, but those that have been done suggest that
the prevalence of overweight and obesity has increased
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Panel 2: Estimating the prevalence of diabetes in sub-Saharan Africa
Several different estimates exist for the prevalence of diabetes in countries in the
sub-Saharan African region. These estimates vary depending on the method used to
ascertain the diagnosis (eg, self-report vs biomarker) and, for biomarker-based diagnosis
only, the biomarker used (eg, fasting glucose vs 2 h oral glucose tolerance test [OGTT]
vs HbA1C). Even in well studied populations in high-income countries (HICs), debate
continues around which biomarker most reliably predicts long-term macrovascular and
microvascular outcomes of hyperglycaemia and, hence, which should be used to diagnose
diabetes.17,18 No longitudinal studies have been done in sub-Saharan Africa to ascertain the
best method for diagnosis. Thus, whether methods developed in HICs to determine the
prevalence of diabetes can be used to define diabetes and reliably predict the future
burden of clinically relevant outcomes in populations in sub-Saharan Africa is currently
unknown. Studies in this area are urgently needed.
Compounding this uncertainty is that many countries have used the WHO STEPwise
approach to surveillance (STEPS) method to estimate burden,5 which has included use of
fasting glucose to diagnose diabetes. This inclusion could potentially miss patients in the
earlier stages of the disease who would show impaired glucose tolerance in a 2 h OGTT but
would have normal fasting concentrations. The effects of these differences in methods on
cross-sectional prevalence estimates of diabetes have been shown in African and other
settings.19 For example, the prevalence of diabetes in people aged 55 years and older in
Africa was higher when measured with the 2 h OGTT than when measured with fasting
glucose alone (23·9% vs 10·9%) and in non-STEPS studies than in STEPS studies
(17·1% vs 9·6%).20
Results can also be affected by the sampling method used, with many country estimates
coming from samples of convenience rather than from robust methods of sampling.
Sample sizes also vary greatly between studies—for example, in the NCD-RisC study,16
some countries had less than 150 data points and others had tens of thousands.
Geography and demographics should also be considered when interpreting results. For
example, major differences exist in the prevalence of obesity and diabetes between
populations of young and older people.20 Additionally, although high-quality data on the
urban versus rural prevalence of diabetes and obesity are scarce, studies from other
countries clearly show differences in prevalence between rural and urban areas and a
change in that distribution over time.21 Detection bias should also be considered, because
underdeveloped health systems in countries in sub-Saharan Africa might lead to
under-reporting of diabetes prevalence compared with HICs, where diabetes is more
reliably detected.
These factors need to be considered when interpreting all studies of diabetes prevalence
in countries in sub-Saharan Africa. Additionally, and importantly, all studies producing
estimates for the region as a whole—and individual countries within that region—
are modelled and often based on little or no data. Even though we have chosen to use
estimates from NCD-RisC16 for illustration, and recognise that this work has utility in
making comparisons across regions and over time, the reliability of the prevalence data
for individual countries in sub-Saharan Africa is questionable.22–24 21 countries in
sub-Saharan Africa had missing data and, in those countries with data, samples were
often small and data were old.
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Panel 3: Genetic drivers of diabetes
Genetics of type 2 diabetes in sub-Saharan Africa
We are not aware of any initiative that has successfully integrated genetic markers into
clinically usable risk prediction scores (especially in low-income and middle-income
countries) or that has used genetics to successfully improve treatment outcomes in
diabetes. Nevertheless, genetics continues to be an area of interest both to funders and
researchers. We question the need for such research investment in a geographical area in
which even the burden of disease is unknown. However, given the interest in the area,
and the possibility that knowledge of genetic susceptibility to diabetes might help define
the scale and direction of the diabetes epidemic in Africa, we present a brief overview of
the field in sub-Saharan Africa.
In global populations, nearly 80 genetic loci have been implicated in susceptibility to
type 2 diabetes,28,29 and about 50% of these risk loci were replicated in a 2015 study of
three sub-Saharan African countries enrolled in the AADM study.30 The results of that
study suggested that the genetic architecture of type 2 diabetes in sub-Saharan Africa is
probably characterised by several risk loci shared with populations of non-African
ancestry, and that genetic data from Africans promise to inform the genetics of all human
populations. Epigenetic changes have also been shown to have differential effects on
diabetes incidence depending on the population studied, and such changes might be very
important in African populations given early-life risks of undernutrition.31 Studies30,31 in
sub-Saharan African populations suggest that natural selection has acted on several
genomic regions associated with obesity and type 2 diabetes, and a study32 that mapped
the genetic risk of type 2 diabetes by measuring the allelic frequency of
16 diabetes-associated variants in 51 populations suggested that Africans face the
greatest known genetic risk for type 2 diabetes of any ethnicity studied thus far.
Some knowledge gaps can also be filled by the study of African American populations,
although such comparisons must be interpreted with caution because African Americans
mostly originated from west or central Africa and are therefore not representative of
sub-Saharan Africa as a whole.33 Nonetheless, African American populations clearly have a
two-times increase in the risk of type 2 diabetes compared with Americans of European
origin,34,35 and they also have a much higher prevalence of type 2 diabetes than most African
populations.16 This increased risk of diabetes in African Americans might be an indication of
future trends in Africa. Numerous initiatives linking genetics and cardiovascular risk are
underway in sub-Saharan Africa, including the H3Africa and RODAM studies.
Genetics of type 1 diabetes in sub-Saharan Africa
Little is known about the genetics of type 1 diabetes in sub-Saharan Africa. However, a
study36 of African American populations showed large diversity of
HLA DRB1-DQA1-DQB1 haplotypes and genotypes in African, compared with
European, descendants. Association analyses reproduced several type 1 diabetes risk
effects seen in European-derived haplotypes, while also showing novel effects for
African-derived haplotypes. In particular, the African-specific DR3 haplotype DRB1*0
3:02-DQA1*04:01-DQB1*04:02 was protective against type 1 diabetes.36 Additionally,
the DR4/DR9 genotype, which contains an African-derived DR9 haplotype, conferred
an odds ratio of 30·88 compared with the highest-risk genotypes found in populations
of European origin.36
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in urban areas. For example, Ziraba and colleagues42
used data from Demographic and Health Survey studies
done between 1992 and 2005 in seven sub-Saharan
African countries to show that overweight and obesity
had increased by 35% in women living in urban areas,
and that 31·4% of urban women were overweight or
obese in 2005, ranging from 28–29% in Burkina Faso
and Senegal to 38% in Kenya. However, it seems that

the picture in sub-Saharan Africa is mixed: some
countries show a greater prevalence of overweight and
obesity among urban dwellers, whereas some show a
greater prevalence in rural districts.43 This mixed
picture is probably explained in part by differences in
the pace of the ongoing rural transformation across
Africa.44 Figure 1 shows our analysis of the interactions
between diabetes and obesity in countries in subSaharan Africa.
Overweight and obesity are generally associated with
low socioeconomic status in HICs and high socio
economic status in low-income and middle-income
countries (LMICs), known as the reversal hypothesis.45
However, substantial variation is seen at a more granular
level. For example, in sub-Saharan Africa, Ziraba and
colleagues42 found that overweight and obesity were
more prevalent in women of low socioeconomic status
than in women of high socioeconomic status, with the
most rapid increase in prevalence (50% overall) seen in
the poorest people living in urban areas; the prevalence
of overweight and obesity declined by 10% in women
with secondary education or higher. Conversely, AitsiSelmi and colleagues46 found a positive association
between education and obesity in two sub-Saharan
African countries (Nigeria and Benin), and a small crosssectional study47 in rural Uganda suggested that obesity
was a greater problem among those of high socio
economic status than among those of low socioeconomic
status. Manne-Goehler and colleagues11 found a strong
education gradient in the self-awareness of overweight
and obesity, suggesting that, in the long term, education
and high socioeconomic status might be associated with
reduced prevalence. Variation in results might also
depend on the definitions of socioeconomic status used
in different studies.
Such heterogeneity in results comparing urban with
rural areas and high with low socioeconomic status is
expected in a rapidly changing environment, but the
paucity of high-quality studies examining these issues
restricts any clear conclusions about links between place
of residence, socioeconomic status, and drivers of obesity.
The scarcity of reliable information also limits the ability
to suggest appropriate interventions.
Poor nutrition during fetal and early life, which is
known to contribute to obesity-related health problems
in later life, especially when combined with subsequent
abundance of food (the so-called thrifty phenotype48), is a
likely problem in sub-Saharan Africa.40 Some high-quality
evidence for this phenomenon is beginning to emerge
from the region. For example, a study49 of 352 Malawian
children (median age 9·3 years) who had been treated for
severe acute malnutrition at an average age of 24 months
showed them to have clear evidence of thrifty growth
compared with sibling and community controls, despite
evidence of catch-up in growth. Further research is
needed to assess the long-term impact of intrauterine
and childhood malnutrition in Africa.
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Cultural factors also affect the prevalence of overweight
and obesity—for example, a large girth is perceived as a
sign of affluence in many countries in sub-Saharan Africa
and is a deeply rooted status symbol conferring influence,
A

health, and attractiveness.50 Excess weight also has positive
connotations in societies in which strong stigma is
attached to weight loss and wasting associated
with HIV/AIDS.10
B
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Figure 1: Age-stratified and sex-stratified prevalence of diabetes and overweight or obesity among adults in 12 countries of sub-Saharan Africa
Reproduced from Manne-Goehler and colleagues, with permission from Elsevier. Each point shows the point prevalence estimate for each age group in each country and the horizontal bars indicate
95% CIs, except for the overall prevalence for each age group, which is also represented but as median and IQR. The data sources and methods are discussed in detail elsewhere11 and a summary is included
in the appendix 1. Efforts to obtain, from WHO, data from the STEPwise Approach to Surveillance (STEPS) surveys done across Africa were unsuccessful.24 We therefore independently approached each
country directly. The complete pooled dataset included 39 062 individuals from 12 countries in the period of 2004–13. (A) We calculated the prevalence of diabetes by age and sex . The surveys included
WHO STEPS surveys done in Benin (2008), Comoros (2011), Guinea (2007–08), Liberia (2011), Mozambique (2005), Tanzania (2012), Togo (2010), and Seychelles (2013); a Demographic and Health
Survey done in Namibia in 2013; and the South Africa Nutrition and Health Examination Survey done in 2012 (appendix 1). We defined diabetes according to the WHO criteria (appendix 1) as either a
fasting plasma glucose concentration of 7·0 mmol/L (126 mg/dL) or higher, a 2 h plasma glucose concentration of 11·1 mmol/L (200 mg/dL) or higher, or an HbA1c measurement of 6·5% or higher. Crosscountry prevalence of diabetes ranged from 1·3% in Benin to 21·6% in Seychelles, based on fasting blood glucose measurement and self-reported use of diabetes medications. The analysis showed a strong
association between increasing age and the prevalence of diabetes, with the prevalence reaching around 30% in men and women aged 55–64 years in South Africa and Seychelles. A higher prevalence in
women than in men was seen across all age groups. (B) We calculated the prevalence of overweight or obesity by age and sex. Overweight or obesity was defined as a BMI of 25 kg/m² or higher. The analysis
showed a strong association between increasing age and the prevalence of overweight or obesity, with a higher prevalence in women than in men across all age groups. Prevalence of overweight or obesity
also varied across countries, with age-stratified levels ranging from less than 10% in men aged 25–39 years in Benin and Togo, to more than 70% in South Africa, and to almost 80% in women aged
55–65 years in Seychelles.
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Population trends and ageing
The population aged 20–79 years in sub-Saharan Africa is
projected to increase from 441 million in 2015 to
926 million in 2040.51 Given the association between
diabetes and older age, this increase will be an important
driver of the increase in the number of people with
diabetes. Furthermore, increasing life expectancy is a
notable feature of populations in sub-Saharan Africa,
especially in countries with a high HIV prevalence and in
which life expectancy is increasing with the rollout of
antiretroviral therapies.52 Although large-scale, highquality studies from sub-Saharan Africa are scarce, a
2016 systematic review20 of studies published between 2000
and 2015 estimated the prevalence of diabetes to be 13·8%
(95% CI 13·2–14·3) in those aged 55 years or older. Given
the potential impact of an ageing population on the
prevalence of diabetes in sub-Saharan Africa, it is essential
for health-system planning that high-quality, local
information is obtained on the association between ageing
and diabetes. See figure 1 for an analysis of the association
between diabetes and age in sub-Saharan Africa.

Type 1 diabetes in sub-Saharan Africa
Type 1 diabetes can occur at any age, with a peak onset
around the time of puberty in western countries. A later
peak from around 15–25 years is often reported in
Africa.53 With increasing age, the clinical distinction
between types of diabetes can also seem blurred, which
further compounds the issue of ascertaining the true
lifetime prevalence of type 1 diabetes.
The incidence of type 1 diabetes began to rise in western
populations around the middle of the last century, and is
still increasing in many parts of the world.54 The rapidity
of this increase points to environmental causes
superimposed upon genetic susceptibility. For example,
Ethiopian immigrants to Israel developed type 1 diabetes
at higher rates than their counterparts in Ethiopia; this is
thought to be due to genetically predisposed individuals
being exposed to new environmental triggers in Israel.55
Earlier age of onset is associated with higher degrees of
genetic susceptibility (panel 3), and the secular trend
towards earlier onset in western populations suggests
increased penetrance of the disease; a similar shift has
also been reported in Rwanda.56
The incidence of type 1 diabetes varies widely with
geography, and a difference in the incidence of childhood
type 1 diabetes of more than 350 times between
populations has been described (from an age-adjusted
incidence of 0·1 per 100 000 population per year in China
to 36·8 per 100 000 population per year in Sardinia).57
Therefore, the incidence from one area cannot be easily
extrapolated to another. Unfortunately, information about
prevalence and incidence from sub-Saharan Africa is
scarce. For example, estimates used in the 2015 IDF Atlas25
were extrapolated from studies in only five countries
(Ethiopia, Nigeria, Rwanda, Tanzania, and Zambia). From
the existing evidence, it seems that the incidence of type 1

diabetes in sub-Saharan Africa is relatively low compared
with many other parts of the world. However, small poorquality studies, and the limited ability of health systems to
diagnose the condition, means that the true prevalence
remains obscure.58 Indeed, recent evidence from Rwanda
suggests that the low apparent prevalence of type 1
diabetes in sub-Saharan Africa is very likely to represent
failure of diagnosis or high mortality in diagnosed cases,
because numbers increase sharply when interventions
become available (see appendix 2 for profile of Rwanda).59,60
An additional limitation of studies is that estimates have
generally focused on children younger than 15 years and
therefore do not account for a substantial proportion of
people with disease onset after this age. The only
published prevalence figure to cover the entire young
adult age group came from Rwanda and was 16·4 per
100 000 population younger than 26 years.61,62 In Rwanda,
there are 3·5 times as many cases of type 1 diabetes in the
population younger than 26 years as in the population
younger than 15 years.

Other forms of diabetes in sub-Saharan Africa
Other forms of diabetes in the region might constitute a
greater proportion of cases than the 5% seen in HICs.26
Of particular note, in Ethiopia, many cases of diabetes
that had previously been considered to be type 1 are now
being reconsidered in light of antibody studies that have
not shown the presence of antibodies typical of the
disease.53
Malnutrition-related diabetes has been reported in subSaharan Africa, but its classification as a distinct subtype
has been controversial, despite several cases being
reported in the literature.50,53 Also known as fibrocalculous
pancreatic diabetes, malnutrition-related diabetes is
usually seen in underweight, malnourished patients and
is characterised by severe hyperglycaemia without
ketosis, high insulin requirements, and the absence of
autoimmunity.
Variant forms of diabetes have been described in people
of African descent since the 1950s. Reports from African
American populations indicate that so-called variant
diabetes is seen in new-onset patients, typically middleaged, overweight, and with a family history of type 2
diabetes in 80% of cases. Despite presentation with
ketosis, such individuals can usually be managed without
insulin.63 The extent to which this represents a true
variant of diabetes remains uncertain, and it is clear that
there is the need for more detailed investigation of the
pathophysiology of diabetes in people of African descent.
We discuss gestational diabetes in sub-Saharan Africa
in panel 4.

Complications of diabetes
Overview

As discussed extensively in panel 2, there is insufficient
high-quality evidence to estimate the burden of diabetes
in sub-Saharan Africa or to obtain reliable data about
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Panel 4: Gestational diabetes and hyperglycaemia in pregnancy
Causes
Relative insensitivity to insulin is a normal feature of pregnancy
and gestational diabetes occurs when pregnancy results in
overt hyperglycaemia. Because a fetus exposed to
hyperglycaemia overproduces insulin, which can lead to
macrosomia, obstetric difficulties might result.64 In addition to
being caused by gestational diabetes, hyperglycaemia in
pregnancy might also be due to pre-existing diabetes or
diabetes that manifests for the first time during pregnancy.
Maternal BMI and risk of gestational diabetes are highly
correlated,65 and hyperglycaemia in pregnancy is becoming
increasingly common in parallel with the increased prevalence
of diabetes and obesity in the background population.
Increasing global trends in maternal overweight and obesity
have been reviewed extensively by Poston and colleagues.65
In sub-Saharan Africa, Demographic and Health Surveys show
wide variation in the prevalence of obesity in women of
childbearing age, ranging from 0·7% in Madagascar to 26·8% in
Lesotho. Although maternal underweight has previously been
of great concern in the region, it is now less common than
excess weight in women of childbearing age.66
Prevalence
The global prevalence of hyperglycaemia in pregnancy was
estimated to be 16·9% in 2013, equating to 21·4 million
livebirths.65 More than 90·0% of cases were estimated to occur
in low-income and middle-income countries, and 16·0% were
attributed to pre-existing diabetes or diabetes manifesting for
the first time during pregnancy, leaving around 64·0% due to
gestational diabetes. However, the prevalence might vary by
region depending on the diagnostic criteria used.67
Unfortunately, studies reporting the different causes of
hyperglycaemia in pregnancy in sub-Saharan African countries
are rare.
Scarce information exists about the prevalence of gestational
diabetes in sub-Saharan Africa. A 2014 systematic review67 of
gestational diabetes in the African continent found a
prevalence of gestational diabetes ranging from 0% in Tanzania
to 13·9% in Nigeria. The authors comment that “it is alarming
that very little appears to be known about gestational diabetes
in Africa”, and only six countries (five in sub-Saharan Africa)
provided data of sufficient quality for inclusion in the review.67
Additionally, diagnostic criteria differed between studies and
increased prevalence was seen in studies done after the year
2000 and in those that used more current diagnostic criteria.
Diagnosis of gestational diabetes
It is recommended that screening for gestational diabetes is
done between 24 weeks and 28 weeks of gestation with the
75 g oral glucose tolerance test (OGTT). However, differences
exist between organisations’ diagnostic criteria for gestational
diabetes, and criteria for gestational diabetes have changed
over time.67 This variation in criteria makes comparing studies
and synthesising results from studies challenging, both within
sub-Saharan Africa and globally. For example, a study68 of

around 1000 pregnant women screened for gestational
diabetes between 24 weeks and 34 weeks of gestation in a
single clinic in Nigeria with the OGTT found the prevalence of
gestational diabetes to be 3·8% when 1999 WHO criteria69
were used, 8·1% when 2013 WHO criteria70 were used, and
8·6% when International Association of Diabetes and
Pregnancy Study Groups Consensus Panel (IADPSG) criteria71
were used.

For more on the RODAM study
see http://www.rod-am/eu/
content/objectives
See Online for appendix 2

After the results of the HAPO study72 were reported in 2008,
many groups revised their guidelines. In particular, the IADSPG
and WHO 2013 (similar to IADSPG) criteria differ from older
criteria or those used by other organisations; only one
abnormal value, rather than two, is needed to diagnose
gestational diabetes, and the fasting glycaemic thresholds
used to diagnose glycaemia are lower than previous criteria.67
The new criteria will probably result in an increased prevalence
of gestational diabetes, with knock-on effects on burden to
health systems. For a full review of the diagnostic criteria for
gestational diabetes, see the review by Ma and colleagues.64 It
should also be noted that the HAPO study—on which the
IADSPG and WHO 2013 criteria are based—investigated
outcomes of hyperglycaemia in pregnancy in a non-African
population, and outcomes might be different in populations
that are distinct from the original study population.73 Further
research is needed to ascertain whether the new IADSPG and
WHO 2013 criteria are applicable to populations in
sub-Saharan Africa in terms of their ability to predict adverse
maternal and offspring outcomes.
Risk factors for gestational diabetes in sub-Saharan Africa, as
elsewhere, are gestational diabetes in a previous pregnancy,
family history of type 2 diabetes, previous stillbirth or child with
macrosomia, and maternal age of 30 years or older. It is not
clear whether sub-Saharan African women are at increased risk
of gestational diabetes compared with other ethnic groups. In a
multi-ethnic society such as the USA, women from southeast
Asia were found to develop gestational diabetes at lower BMI
than women of European, Hispanic American, or
African American origin, and it was estimated that two-thirds
of gestational diabetes cases in African Americans could be
prevented if all women were of normal weight when they
entered pregnancy.74
Complications and treatment of hyperglycaemia in pregnancy
Complications include pregnancy-induced hypertension and
pre-eclampsia, antepartum haemorrhage, complications of
labour, preterm birth, birth trauma, congenital anomalies, and
high perinatal mortality.64,65 Women with gestational diabetes are
at a high risk of developing subsequent type 2 diabetes, and their
offspring have increased susceptibility to glucose intolerance and
obesity later in life. Additionally, the risk of diabetic retinopathy
during pregnancy is nearly twice that in the non-pregnant state.75
The rate of complications is greater in pregnancies with preexisting diabetes than in those without.64,65,76
(Continues on next page)
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(Panel 4 continued from previous page)
Relatively little is known about the maternal or offspring
outcomes of pregnancy in women with pre-existing diabetes in
sub-Saharan Africa, other than from a few previous studies,77–79
which had small sample sizes or were published years ago and
so have little relevance to the current situation in the region.
The increasing prevalence of obesity, and its associations with
gestational or type 2 diabetes, in women who are of
reproductive age, could have a great impact on both women

trends over time. The same is true when considering the
burden of diabetes-related complications. In particular,
detection bias probably has a large effect on the reporting
of complications of diabetes in countries where health
systems are not sufficiently developed to provide highquality services, and where health-care-seeking behaviour
is low. Additionally, evidence suggests that hyperglycaemia
in patients in sub-Saharan Africa is detected at a later
stage than in patients in HICs.10 Therefore, given the
longer lead time of hyperglycaemia before treatment is
given, patients in sub-Saharan Africa might appear more
susceptible to complications than their peers in other
countries. A scarcity of data systems in many countries is
a major hurdle to adequate documentation of
complication rates; WHO found that only 17% of
countries in sub-Saharan Africa had any form of diabetes
registry (although WHO did not report the geographical
coverage of, or the quality of, information in those
registries).83 Additionally, the quality of the data reported
will inevitably vary in line with the ability of health
services to record and retrieve information related to
complications of diabetes. Although we present in the
sections below the highest-quality evidence available for
illustrative purposes, the evidence is probably not a good
representation of complications in the entire region. We
do not discuss interactions between diabetes and
infectious diseases, which are of particular relevance to
sub-Saharan Africa, where high rates of infectious disease
coexist with an increasing prevalence of NCDs including
diabetes. These interactions have been extensively
reviewed elsewhere;84–87 comprehensive coverage of these
areas are beyond the remit of this Commission.

Death
The 2015 GBD study9 estimated that, in 2013, diabetes
contributed to an average of 145 189 deaths (uncertainty
interval 129 914–164 809) in sub-Saharan Africa, which
amounted to 1·8% (1·68–1·97) of all deaths in the region.
These figures should be interpreted with caution given
the inadequate recording of cause of death in subSaharan Africa. Indeed, given the prevalence of diabetes
in the region, and the inadequacy of many health systems
to effectively diagnose and treat diabetes and its
complications, this estimate seems very low.
632

and their offspring. That so little is known about these issues in
sub-Saharan Africa is cause for serious concern.
Treating hyperglycaemia during pregnancy in women in
sub-Saharan Africa might be no different to treating women in
other countries. However, all studies identified by this
Commission about the management of hyperglycaemia in
pregnancy in sub-Saharan African populations have been
observational;78,80–82 randomised trials comparing treatments in
sub-Saharan Africa are urgently needed.

Little is known about the causes of death due to chronic
complications of diabetes in sub-Saharan Africa.10 This
knowledge deficit is due to the scarcity of high-quality
vital registration systems in sub-Saharan Africa and poor
diagnostic facilities. Some countries in the region use
verbal autopsies in sample populations to determine the
cause of death, which give estimates at the population
level. A 2014 study88 from the INDEPTH network of
Health and Demographic Surveillance System sites
suggested that diabetes contributed little to mortality
caused by NCDs in Africa compared with that caused by
cardiovascular diseases and cancers. However, this
method might not have captured diabetes as a contributor
to death if it was not ascertained as a direct cause of death.
There is also insufficient data from the region on acute
mortality due to diabetes, although the Commissioners’
experiences and opinions suggest that acute mortality
caused by diabetes in sub-Saharan Africa is most often
due to undiagnosed or inadequately treated type 1
diabetes, which rapidly progresses to diabetic ketoacidosis
and death. Early reports from sub-Saharan Africa
document a very high mortality for type 1 diabetes. In
Mali during the 1990s, 50% of patients died within 2 years
of a type 1 diabetes diagnosis,89 and a study90 published in
2005 estimated the life expectancy of children younger
than 15 years in Mozambique to be 3·5 years after
diagnosis; a child in a rural area who developed diabetes
was unlikely to survive for more than 1 year. Data on
mortality of people with type 1 diabetes from some other
countries suggested less severe outcomes. In Soweto,
South Africa, mortality due to type 1 diabetes was 16% in
the period of 10 years between 1982 and 1992 (with half of
the deaths being from renal failure and the remaining
deaths being from ketoacidosis, hypoglycaemia, or
sepsis), although a follow-up study showed 43% mortality
after 20 years of follow-up.81 Data from Rwanda in 2015
suggested a 5 year survival of 93·8%.25 However, it is
unlikely that these data reflect the true mortality of type 1
diabetes in Rwanda because a substantial amount of data
were missing and participants could potentially have
been subject to the Hawthorne effect. It is possible that
mortality for type 1 diabetes in Rwanda could have been
as high as three times the crude mortality rate of 13·9 per
1000 patient-years.25
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Although reliable data from sub-Saharan Africa are not
available, the small number of studies that have been
done can still be taken to reflect a state of care that is far
below standards seen in more affluent parts of the world,
where life expectancy for young people diagnosed with
type 1 diabetes is now only a few years less than that of
the general population.91

of late diagnosis and poor glucose control. Thus, if
reliable evidence was available, we suspect that the
prevalence and severity of complications of diabetes in
the region would far surpass reports from studies of
HICs. This deduction is of concern, given that health
systems in sub-Saharan Africa are already struggling.

Chronic complications of diabetes

The manifestations of diabetes that affect sight are
diabetic retinopathy, proliferative retinopathy, and
maculopathy, all of which are preventable and treatable
before vision is lost.93 Cataracts are prevalent among
patients with diabetes in Africa, but much of the
literature has focused on diabetic retinopathy, which is
where we focus our discussion.
Globally, diabetic retinopathy accounts for 2·6%
(95% CI 2·2–3·4) of all blindness,94 and age-standardised
prevalence of retinopathy as a cause of blindness was
found to be highest in sub-Saharan Africa, at 0·14%
(0·10–0·20).94 The most up-to-date systematic review95 of
the prevalence of diabetic retinopathy in people with
diabetes in sub-Saharan Africa was published in 2013. The
authors of that review95 included 62 studies from
21 countries in the region and, accepting recognised
differences in diagnoses and sampling techniques, the
prevalence in population-based surveys was 30·2–31·6%
for diabetic retinopathy, 0·9–1·3% for proliferative
diabetic retinopathy, and 1·2–4·5% for any maculopathy.
Those numbers were roughly similar to the global
reported prevalence,96 which is surprising given the poor
access to services for the diagnosis and treatment of
hyperglycaemia in sub-Saharan Africa, although it is likely
that poor access to health systems and reporting in subSaharan African populations result in underestimation of
prevalence.

The chronic complications of diabetes affect blood
vessels and are conventionally subdivided into
macrovascular and microvascular; however, they also
affect other tissues, including nerves and the optic lens.
Little is known about the prevalence, age of onset, or
rate of progression of diabetic complications in subSaharan Africa, and most evidence comes from small,
single-country, single-centre, and somewhat out-of-date
studies. A systematic review92 that used GBD methods
calculated that the non-fatal burden of diabetes in total
years lost due to disability in South Africa in 2009
was 73 714; 42 919 (58·2%) from diabetes alone,
13 458 (18·3%) from retinopathy, 4527 (6·1%) from
amputations, 7233 (9·8%) from attributable stroke
disability, and 5577 (7·6%) from attributable ischaemic
heart disease disability. Additionally, the GBD 2015
study9 estimated that diabetes contributed to 5 556 560
(uncertainty interval 4 753 194–6 442 898) DALYs in 2013,
which corresponded to 1·05% (0·94–1·16%) of all
DALYs in sub-Saharan Africa. Such estimates are
necessarily imprecise and, as previously discussed,
seem low given the estimated prevalence of diabetes in
sub-Saharan Africa and the poor access to health
systems for management of hyperglycaemia.
The scarcity of reliable data is highlighted as a
limitation in all reports of specific complications in subSaharan Africa. For example, a 2011 systematic review26
of the prevalence of chronic complications of diabetes in
the region found only 23 eligible studies. The recorded
prevalence of retinopathy varied from 7% in Kenya
to 63% in South Africa, of neuropathy from 27% in
Cameroon to 66% in Sudan, and of microalbuminuria
from 10% in Tanzania to 83% in Nigeria. Macrovascular
complications were not covered, and a search of the
literature done by the Commission did not return any
studies addressing the prevalence of cardiovascular
complications. The most recent regional narrative review
was done by Levitt10 in 2008, who noted that ischaemic
heart disease was less common in indigenous Africans
with diabetes (5–8% based on electrocardiogram stress
tests and 4% based on history) than in their counterparts
of European heritage (23% based on positive history).
Levitt also noted that there was little available evidence
on the risk of stroke in people with diabetes.
The available information indicates that vascular
complications develop sooner after a diabetes diagnosis
in sub-Saharan African patients than in those from other
parts of the world,10 which is an inevitable consequence

Diabetic eye disease

Diabetic nephropathy
Globally, the contribution of chronic kidney disease to
deaths nearly doubled between 1990 and 2010, although
improved ascertainment and ageing populations might
have contributed to this increase.97 In 2010, 70% of
patients with end-stage renal failure were predicted to
live in low-income countries (LICs). Hypertension was
the leading cause of death from kidney disease worldwide
in 2010,97 but the number of cases attributable to
hypertension was decreasing by 2013, whereas cases
attributable to diabetes were increasing.98
The true prevalence of both chronic kidney disease and
diabetic nephropathy in sub-Saharan Africa remains
uncertain because of the lack of population-based surveys
and diabetes registries. However, evidence from a
systematic review and meta-analysis99 of studies involving
64 307 people estimated the prevalence of chronic kidney
disease in sub-Saharan Africa to be 13·9% (95% CI
12·2–15·7). The mean age of people in that study99 was
41·4 years (SD 9·9); 46 494 (72%) people had diabetes,
2765 (4%) were obese, 37 169 (58%) were HIV-positive,

www.thelancet.com/diabetes-endocrinology Vol 5 August 2017
Downloaded for Anonymous User (n/a) at Aga Khan Hospital from ClinicalKey.com by Elsevier on September 07, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.

633

The Lancet Diabetes & Endocrinology Commission

and 7845 (12%) had hypertension. These findings should
be interpreted with caution, since only three of 90 studies
were considered high quality. Notably, the estimated
prevalence of diabetes was decreased to 6% in the
21 studies deemed of medium or good quality.99,100 Similar
caution is needed with regards to evidence about the
prevalence of nephropathy in patients with diabetes,
which has in most studies been based on the presence of
proteinuria. A systematic review101 identified 32 studies
from 16 African countries, only two of which were
population-based. That study suggested a prevalence of
proteinuria in patients with diabetes as high as 95% at
10 years of follow-up, with an 18·4% mortality from
nephropathy at 20 years of follow-up.
Studies102 have shown that African Americans have
twice the risk of end-stage renal disease compared with
people of European descent, even after correction for
socioeconomic and clinical risk factors. This increased
risk appears to be due in part to inheritance of an
apolipoprotein L1 (APOL1) gene variant, of which the
high prevalence in west Africa might have been driven by
selection for the protection it confers against some
variants of trypanosomiasis.102 APOL1 has been associated
with accelerated progression of several types of renal
disorder, including increased susceptibility to HIVinduced nephropathy, and might have a similar role in
diabetic nephropathy.103 When factors such as
hypertension, HIV, genetic predisposition, and diabetes
are combined, as is often the case, renal damage is likely
to be accelerated.104 In fact, the average age of onset of
end-stage renal disease in sub-Saharan Africa is
estimated to be 20 years younger than that in HICs.104

Diabetic neuropathy and diabetic foot
Diabetic peripheral neuropathy is probably the most
common complication of diabetes globally, affecting more
than 50% of patients with diabetes.105,106 However, estimates
vary depending on the diagnostic and epidemiological
methods used. Diabetic peripheral neuropathy can be
painless or, less commonly, painful.107 Although well
designed, large, up-to-date, population-based studies are
not available, and this summary should be interpreted
with that in mind, published data from countries in subSaharan Africa suggest that diabetic peripheral neuropathy
is common in the region.105 In the USA, the prevalence of
diabetic foot ulcers was estimated to be 8% of patients
with diabetes,108 whereas the prevalence in sub-Saharan
Africa is thought to be higher. For example, the prevalence
of diabetic foot ulcers was estimated to be 15% in
Tanzania,109 13% in Cameroon,110 and 9·5% in Nigeria.111 In
hospitalised patients with diabetes, as would be expected,
the prevalence of diabetic foot ulcers is even higher,110,111
although limitations of study size apply. The clinical
features of painful diabetic peripheral neuropathy are
similar to those in patients outside of sub-Saharan Africa
and include poor quality of life, insomnia, and
depression.112
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Although, once again, evidence is sparse and not
recent enough to draw clear conclusions, peripheral
neuropathy is thought to be the principal underlying
risk factor for foot ulceration in patients with diabetes
in sub-Saharan Africa.113,114 This differs from HICs, in
which peripheral arterial disease is closely associated
with the development of diabetic foot disease.115 The
pattern seems to be changing, however, with the
prevalence of peripheral arterial disease increasing
rapidly in people with diabetes in sub-Saharan Africa.
Compared with a prevalence of less than 10% in
the 1990s, more recent studies have shown an increased
prevalence of peripheral arterial disease of between 20%
and 54%.116–118
In addition to diabetic peripheral neuropathy and
peripheral arterial disease, multiple environmental
factors are associated with both the occurrence and
severity of diabetic foot disease—for example, bare-foot
walking (which might be cultural or related to an inability
to afford shoes); ill-fitting shoes; or rodent bites on feet,
particularly in people who sleep on the floor.113,119
In sub-Saharan Africa, amputations are frequent
outcomes in patients with diabetic foot ulcers. Around a
third of such amputations have been associated with
neuro-ischaemic lesions, progressive infection, or both.120
The in-hospital mortality of patients with severe foot
ulcers (Wagner score >4) managed without surgery or
amputation can be as high as 54%.121 Amputation rates
might also be lower than expected because of difficulty in
obtaining consent for surgery. Sadly, some patients with
severe diabetic foot ulcers discharge themselves from
hospital against medical advice, putting themselves at
high risk of severe sepsis and death at home.

Arterial disease
Cardiovascular disease is modulated by three major
preventable risk factors other than smoking (the
prevalence of which is increasing rapidly in Africa122,123):
hypertension, diabetes, and hyperlipidaemia. Although
obesity largely manifests risk through its effects on these
factors, it is still classed by many investigators as a
modifiable risk factor of cardiovascular disease and is
thus included in this discussion. Together, these risk
factors are thought to account for most deaths from
cardiovascular causes. According to GBD,97 hypertension
remains the leading risk factor worldwide, but diabetes
(and obesity) replaced cholesterol in second place
between 1980 and 2010 for all categories other than
ischaemic heart disease, with the mortality burden
shifting from HICs to LMICs. In sub-Saharan Africa,
obesity and hypertension are thought to be the most
common cardiovascular risk factors, although issues of
insufficient reliable data apply.124 We have discussed
obesity earlier in this report. The prevalence of high
blood pressure has increased rapidly in the past
2–3 decades and, according to the WHO STEPwise
approach to surveillance (STEPS) surveys done in
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sub-Saharan Africa,125 the prevalence of high blood
pressure ranges from 19·3% in Eritrea to 39·6% in
Seychelles. It is estimated that 150 million people living
in sub-Saharan Africa will be treated for hypertension by
2025 compared with 80 million in 2010, an increase
attributed to excessive alcohol consumption, reduced
physical activity, and adoption of western diets and other
features of the economic transition.125
The extent of co-association of cardiovascular risk
factors in individuals with diabetes is even less well
known. Recent studies have estimated that, among
patients with diabetes in sub-Saharan Africa, the
prevalence of hypertension ranges from 44% to 76%.126–129
Little is known about the prevalence of hyperlipidaemia
in patients with diabetes in sub-Saharan Africa, and the
prevalence of metabolic syndrome among people with
diabetes in clinical settings in the region ranged
from 25% to more than 90%, depending on the criteria
used.130 Insufficient high-quality information is also a
major limitation when reviewing the features of people
presenting with cardiovascular disease in sub-Saharan
Africa. For example, a systematic review131 of myocardial
infarction in the region found only seven studies from
five countries that satisfied all inclusion criteria.
Nevertheless, information from another review132
illustrated the heterogeneity of risk factors in patients
presenting with coronary disease: 41·0–66·3% for
hypertension, 22·5–40·0% for diabetes, 8·8–67·3% for
hyperlipidaemia, 11·8–44·0% for smoking, and
27·0–80·0% for obesity. Sample size was exceedingly
small in all the studies included in the review,132 ranging
from 30 patients to 169 patients, probably reflecting the
inadequacy of record keeping and storage.
A worrying feature of the changing pattern of
cardiovascular disease in sub-Saharan Africa is the
proportion of deaths in people younger than 70 years,
which is still increasing in the region despite decreasing in
many HICs; deaths attributed to cardiovascular disease in
people younger than 70 years contributed to 21% of total
deaths in HICs compared with 58% of total deaths in subSaharan Africa in 2013.9 Thus, cardiovascular disease
seems to be affecting younger, more economically
productive people in sub-Saharan Africa. The scale of the
cardiovascular disease epidemic likely to affect subSaharan Africa awaits clearer definition, and so too does
the pattern. However, cerebrovascular disease is likely to
contribute substantially to the burden of cardiovascular
disease given that it is thought to be responsible for
around 11·23% (95% CI 10·92–11·57) of all deaths
worldwide.9 Stroke is potentially preventable, and a
systematic review133 of worldwide stroke incidence showed
a 42% reduction in incidence in HICs in the four decades
from 1970 to 2008. By contrast, the incidence of stroke has
increased by 100% in LMICs.133 Little is known about the
prevalence of stroke in patients with diabetes in subSaharan Africa, although early reports suggest that it is
low. For example, in a large study134 covering the period

from 1999 to 2012 in a major hospital in urban Cameroon,
and involving 1688 patients admitted for stroke, the
prevalence of diabetes was 12·8%. However, the prevalence
is likely to vary greatly depending on geographical location.

Clinical challenges of diabetes in sub-Saharan
Africa
Diagnosing diabetes in sub-Saharan Africa

The clinical challenges of diabetes in sub-Saharan Africa
are numerous, yet, despite differing levels of development
and population structure, countries within the region face
similar challenges concerning screening, diagnosis, and
management. In this section we consider issues of clinical
relevance, wherein common themes in the inability to
provide quality care are scarcity of knowledge, inability to
reliably access drugs, and poor access to treatments for
complications. Health system considerations will be
addressed in more detail in subsequent sections.
Poor awareness of diabetes, both at population and
health-care-profession levels, means diagnosis is often
delayed. For people with type 2 diabetes, this delay will
generally result in an unequivocally elevated random
glucose at presentation.10,39,135 Choosing the correct cutoff
point or test to use for diagnosis of diabetes (panel 2) is
therefore of less immediate relevance in the context of
routine clinical diagnosis and care in this setting, but the
question of whether the American Diabetes Association
(ADA) guidelines136,137 for diagnosis of diabetes can be
applied to a sub-Saharan African population will become
increasingly important in the future as earlier detection
of diabetes becomes feasible. It is worth noting that,
although HbA1c is increasingly used as a diagnostic tool
in HICs, its use is likely to face challenges in Africa given
that it relies on integrity of red blood cells, which can be
affected by several conditions that are prevalent in subSaharan Africa, such as haemolysis from malaria or
sickle cell disease.
Diagnosis of diabetes is complicated by the poor
availability of diagnostic equipment in clinics, laboratory
facilities to process samples, and transport between
clinics and laboratory facilities (table 3). Therefore,
rather than rely on the gold-standard measures put
forward by the ADA, many practitioners rely on capillary
blood glucose measurements made with point-of-care
instruments and urine strips. However, even these
simple tests are often unavailable. For example, Beran
and colleagues90,139 found that urine glucose strips were
available in only 18% and blood glucose meters in only
21% of health-care facilities in Mozambique. Blood
glucose meters were available in 13% (urine glucose
strips in 54%) of facilities in Mali and in 49% (urine
glucose strips in 61%) of facilities in Zambia.90,139
For people with type 1 diabetes, a delay in diagnosis can
prove fatal. Unfortunately, given that in LICs the
symptoms of type 1 diabetes—rapid weight loss, fatigue,
abdominal pain, and confusion—can easily be mistaken
for AIDS or cerebral malaria,140,141 and that the condition is
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Cost per
person with
diabetes(U$)*

Guidelines
Facilities offering Readiness to
provide diabetes available to
diabetes
treat diabetes*
services†
management*

At least one
trained member
of staff*

Blood
glucose
testing*

Metformin Glibenclamide Injectable
Urine
Urine
capsules*
insulin*
dipstick capsules*
dipstick
proteins* ketones*

Benin (2013)

73·0

33%

44%

10%

5%

31%

52%

26%

22%

29%

7%

Burkina Faso
(2012)

91·0

42%

43%

27%

19%

14%

70%

25%

6%

6%

4%

Kenya (2013)

82·4

37%

..

..

..

..

..

..

..

..

Mauritania
(2013)

89·6

17%

..

38%

16%

25%

33%

26%

9%

8%

12%

Sierra Leone
(2012)

184·4

23%

51%

25%

6%

43%

82%

64%

46%

35%

20%

Tanzania
(2012)

95·5

12%

51%

30%

34%

40%

..

..

57%

52%

34%

Uganda
(2013)

No estimate

34%

60%

83%

31%

80%

61%

..

49%

55%

15%

32%

57%

43%

20%

51%

67%

..

36%

70%

39%

Zambia (2010) 186·6

..

Data are % of facilities unless otherwise specified. Income status for each country (all are low income) was determined by data from the World Bank (2014). *Data are from country Service Availability Readiness
Assessment reports. †Data are from the International Diabetes Federation 2015 Diabetes Atlas.25
138

Table 3: Service delivery indicators for facilities offering diabetes diagnosis, management, or both, by low-income country

relatively rare, anecdotal reports and small studies suggest
that diagnosis is often delayed. Indeed, Makani and
colleagues141 found that 21 (11%) of 199 patients diagnosed
with cerebral malaria in Tanzania actually had diabetes.
We discuss diagnosis of gestational diabetes in panel 4.

Managing hyperglycaemia in sub-Saharan Africa
Effective glycaemic control is essential for short-term
wellbeing
and
long-term
protection
against
complications. Available evidence suggests that many
people with diabetes in sub-Saharan Africa fail to achieve
adequate glycaemic control, although studies specifically
addressing this issue have been small.142–144 Good
glycaemic control is most likely to be achieved when a
patient has reliable access to clinical services, when the
availability of equipment to monitor control is good,
when patients and health-care professionals have good
knowledge about diabetes management, and when
efficacious and affordable treatment is available and
backed by adequate and effectively deployed measures of
glucose control. In sub-Saharan Africa, barriers are
experienced at each of these steps. Manne-Goehler and
colleagues11 found that only around one-fifth of
overweight or obese people at high risk of diabetes
remembered ever being offered blood glucose testing,
that just over one-third of those who were identified as
having diabetes remembered ever having a test done,
and that only one-quarter were on medication.
The ability to monitor glycaemic control per se in subSaharan Africa is difficult, even in hospital settings. For
example, in a survey of six countries done in 2011,128 only
around 47% (range 27·5–81·1) of patients with diabetes
had had HbA1C measured in the 12 months before the
study. In primary care settings, the situation is probably
worse; however, we could not find any published data
from sub-Saharan Africa. The availability of other
methods for measuring glycaemia in the clinical setting
636

was discussed earlier. As discussed in panel 2, the choice
of test to monitor long-term glycaemic control is a key
consideration and, although HbA1C is the test of choice in
many centres in sub-Saharan Africa,39 whether
measurement of HbA1C is the best test for a sub-Saharan
African population is unclear. Other methods of
monitoring glycaemic control, such as measuring
concentrations of fructosamine or glycated albumin,17
might be beneficial in populations for whom HbA1c is not
reliable. These tests are not, however, widely available in
sub-Saharan Africa, and their potential value in the
region needs to be explored further.
Limited access to home blood glucose monitoring
equipment adversely affects patient education and
empowerment, which is a mainstay of diabetes
management.145 The median cost of a blood glucose strip
in seven African nations was US$0·50 (range $0·20–$1·20),
and the yearly cost of consumables for minimal reasonable
care to families with a child or young person with diabetes
in these countries ranged from 74% to 377% (median 126%)
of per-capita gross national income.146
The first step of type 2 diabetes treatment in HICs is
lifestyle advice, but few patients in sub-Saharan Africa
receive such advice. Additionally, most people with type 2
diabetes require drug treatment, with the most
commonly available drugs being metformin and
sulfonylureas, or insulin for those who do not respond to
treatment with these drugs. Affordability should not, in
principle, be an obstacle to treatment, since these drugs
are potentially available at low cost. Unfortunately, as
discussed later in this report, supply-chain problems and
price mark-ups are such that simple therapies are often
unavailable or unaffordable at the patient level.
Newer and more expensive treatments are actively
marketed in all parts of the world147 and might have
advantages in certain subgroups of patients,148 although
there are few outcome studies to show that they can
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In view of the huge costs involved in managing the
complications of diabetes, and the increasing burden of
diabetes, strategies to prevent complications are
desperately needed in sub-Saharan Africa. Adequate
management of hyperglycaemia and other risk factors,
and regular assessment for early evidence of
complications, are the cornerstones of successful
strategies to prevent microvascular and macrovascular
complications. Diabetes registries have been highly
successful platforms to drive improved outcomes in
these regards in HICs, but issues with availability of
technology and other necessary infrastructure mean that
such registries are largely absent in sub-Saharan Africa.83
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Overall, cardiovascular disease risk is logically addressed
by treating overall risk rather than by focusing on
hyperglycaemia alone.152 This approach presents
challenges, but the Steno-2 study153 was a striking
demonstration of the benefits of multifactorial
intervention in type 2 diabetes. Wherever possible,
people with diabetes should have regular assessments
for all risk factors of cardiovascular disease. However,
studies in sub-Saharan Africa have shown the difficulties
of such concomitant services. For example, in a slum in
Nairobi, Kenya, Werner and colleagues154 found that
only 3·4% of people attended cardiovascular risk clinics
on a regular basis during 34 months of follow-up.
Adherence to recommended practice among medical
professionals is also low, with many doctors in a
cardiovascular risk clinic failing to follow guidelines for
concomitant assessment of cardiovascular risk.155
Additionally, the guidelines for risk evaluation and
reduction in sub-Saharan Africa are inconsistent, often
focusing on single risk factors, and are generally
adaptations of guidelines from other settings.156 More
evidence from local settings is urgently needed to feed
into local guidelines.

Monitoring and managing complications of diabetes

l in

Management of coexisting risk factors

Although this Commission focuses on diabetes and total
cardiovascular disease risk, we would be remiss if we did
not mention that the reduction of cardiovascular disease in
sub-Saharan Africa requires a concerted effort to reduce
hypertension, given the high prevalence of hypertension
in the region. A 2014 systematic review157 of 33 surveys
involving more than 110 000 participants in sub-Saharan
Africa found a pooled prevalence of hypertension of 30%,
but only 27% of people with hypertension were aware of
their status before the surveys, only 18% were on treatment,
and only 7% had acceptably controlled blood pressure. In
fact, the World Heart Federation158 puts both tobacco and
blood pressure control in third place in its nine steps to
reduce global burden of cardiovascular disease and does
not mention control of hyperglycaemia. However, given
that diabetes and hypertension often co-occur and interact
synergistically to increase cardiovascular risk, the burden
of diabetes is likely to increase in sub-Saharan Africa, and
the adverse effects of diabetes go beyond those of
cardiovascular disease, diabetes must be considered an
important risk factor.

Fu
l

achieve cost-effective reductions in morbidity or mortality
compared with the three basic medications (metformin,
sulfonylureas, and insulin). The pressing need, therefore,
is to ensure that these basic medicines are available
throughout sub-Saharan Africa and that clinicians are
well educated about the ability to treat diabetes with
simple agents (panel 1).
For type 1 diabetes, the essential therapy is insulin.
Unfortunately, insulin and other components of care are
often either unavailable in health-care systems or
unaffordable to patients. These issues have been
extensively reviewed elsewhere60,149 and are summarised
in figure 2. Safe insulin storage is also a problem for
many families who do not have access to refrigeration
and so use clay pots for evaporative cooling.
Encouragingly, evidence indicates that this method is
effective in reducing storage temperatures towards
standard room temperature of 20–25°C.150 In addition to
treating the disease, health-care providers need to
recognise that the emotional impact on young people
with type 1 diabetes and their families is often severe,
especially in countries with relatively low health literacy.151
Knowledge can help to mitigate this burden, and, given
the complexity involved in the management of type 1
diabetes, diabetes education of young patients, their
families, and health professionals—tailored to culture,
language, and education or knowledge levels—is critical
to achieving good outcomes. Several non-governmental
initiatives exist to provide care for people with type 1
diabetes in sub-Saharan Africa (appendix 1).
We discuss management of gestational diabetes in
panel 4.

Figure 2: Provision of care for children with type 1 diabetes in 20 African and 14 European countries
Percentages of study countries providing 12 key components of diabetes care are shown. Data are from a
subanalysis of data from the 2015 study by Ogle and colleagues.60
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The availability of management strategies to prevent
progression or treat complications of diabetes is
generally poor in sub-Saharan Africa. Challenges in
prevention and management of diabetic retinopathy and
nephropathy illustrate the issues in the region.
Prevention and management of diabetic retinopathy
requires both good glycaemic control and timely
detection and treatment (with photocoagulation) of
early-stage, sight-threatening retinal changes. However,
there are insufficient numbers of ophthalmologists
(about 1 per 1 000 000 population) or opticians in the
region to perform opportunistic screening for diabetic
eye disease.159,160 Non-physician cadres, such as
ophthalmic clinical officers, receive relatively little
training in retinal disease, and eye services are
overwhelmed by other conditions.161 Use of mobile
digital photography with telemedicine links is a potential
solution to deliver cost-effective, accessible screening to
rural and remote populations and, given that fundus
cameras remain prohibitively expensive (cost in the
region of US$15 000), validation studies are being done
for several portable fundus cameras.162,163 A simple risk
score could be an attractive alternative to screening by
retinal fundus photography to identify those who are
more likely to be diagnosed with retinopathy (or any
other major complications) for transfer to screening and
treatment hubs. However, less than 30% of countries
have treatment facilities for retinal photocoagulation.83
The prognosis of diabetic nephropathy in populations
in HICs has greatly improved over recent decades because
of primary prevention (good glucose and blood pressure
control) and secondary prevention (regular screening for
proteinuria and treatment with an angiotensin-converting
enzyme inhibitor after the onset of proteinuria).
Furthermore, dialysis and renal transplantation have
greatly extended the prognosis of patients with end-stage
disease.153 Unfortunately, many patients with diabetic
nephropathy in sub-Saharan Africa might not have access
to such treatments and often progress to end-stage renal
disease.100,164 Additionally, many parts of sub-Saharan
Africa have no nephrologists at all (Kenya has one per
2 million population and South Africa has just over
one per million),101 and dialysis is unaffordable to many
patients.104 See the appendix 1 for examples of successful
initiatives in sub-Saharan Africa for diabetic retinopathy
and diabetic foot disease.

Screening and prevention of type 2 diabetes
The Commission’s consensus is that the best way to
manage the diabetes epidemic facing sub-Saharan
Africa is to prevent the change in dietary habits and
decline in physical activity leading to overweight and
obesity that are pervasive across the region. The social,
economic, cultural, and political elements that are
needed to ensure prevention of these changes are far
beyond the remit of this Commission, however, and
readers are referred to other extensive literature on this
638

subject—for example, as summarised in The Lancet
Physical Activity Series.165
Evidence indicates that screening for diabetes in HICs is
not beneficial in terms of effect on long-term outcomes.166
Additionally, no evidence from LMICs suggests that
screening would be a valuable approach to successfully
identify and manage people with diabetes or
hypertension.167 Nevertheless, given the huge number of
people in sub-Saharan Africa who have diabetes and go
undiagnosed, many academics and policy makers
maintain that targeted screening should be done to enable
earlier identification and treatment.168 Whether such
targeted screening will work in practice in LMICs, the risk
scores that would be effective for selecting patients to
screen, what level of health system infrastructure is
needed to enable it, and the cost-to-benefits ratios of
instigating such screening are currently unknown.
Research is urgently needed to answer these questions
before putting in place potentially costly screening
programmes. It has also been suggested that platforms
for detection of communicable diseases could be co-opted
to screen for diabetes and cardiovascular risk factors.
Again, however, there is no evidence that such platforms
would be a cost-effective method for improving outcomes,
and research in this area is needed.52

The next steps
The factors limiting access to prevention and management
options for diabetes, its associated cardiovascular risk
factors, and long-term complications in sub-Saharan
Africa are similar. These factors are poor understanding
of diabetes and its complications among health-care
professionals and patients; delays in seeking medical
attention and in patient referral for specialist care; poor
control of glycaemia and other risk factors; inability of
patients to afford treatment or transport to attend
treatment facilities; and, in some cases, a preference by
patients for alternative traditional therapies.
Thus far, we have illustrated the difficulties in provision
of good care for patients with diabetes in sub-Saharan
Africa. We have also given some examples of successful
strategies in HICs, although whether these strategies are
transferable to sub-Saharan Africa requires further
research. Additionally, diabetes affects multiple
physiological systems and interacts with many other
diseases to increase the risk of adverse outcomes for a
patient. Therefore, a broad-based, health-systemimprovement strategy will clearly be central to improving
outcomes in diabetes. In the following sections of the
report, we move from clinical considerations to
considering the health-system approaches that are
necessary to support clinical aims.

Health-system responses to diabetes in
sub-Saharan Africa
Although health systems are crucial in a successful
response to diabetes, most research on diabetes in
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sub-Saharan Africa has focused on epidemiology and
clinical presentation, with a few studies83,169 exploring
health systems, although these were limited in scale
and scope. We reviewed published studies and analyses
of surveys to explore health-system responses to the
increasing burden of diabetes in sub-Saharan Africa.
We used an established health-systems framework to
guide our analysis, and we systematically examined the
response to diabetes with regard to the key healthsystem functions of organisation and governance,
financing, resource management, and service delivery.170

Organisation and governance of diabetes in
health systems in sub-Saharan Africa
The state capacity, organisational and governance
structures, and institutional strength of health systems
vary across sub-Saharan Africa. In 2010, 42 countries in
the WHO African region reported having a unit or
department within their ministries of health with
responsibility for NCDs,171 but just seven countries had
a national operational policy, strategy, or plan for
diabetes. This situation has ostensibly improved, and,
in 2015, the WHO report83 on assessing national
capacity to address and respond to NCDs—where
35 (75%) of 47 countries in the WHO African region
responded to the survey—stated that 100% of countries
in the WHO African region that responded to the
survey reported having a unit, branch, or department in
their ministry of health that was responsible for NCDs.
Additionally, 72% of countries had an operational
policy, strategy, or action plan that integrated NCDs and
their risk factors. However, looking specifically at subSaharan Africa,171,172 only 20 countries reported having
an operational policy, strategy, or action plan for
diabetes (nine countries did not and the remainder did
not respond).
In 2010, the availability and the stage of implementation
of guidelines, protocols, or standards for diabetes
management varied across countries. Just four countries
in the WHO African region that responded to the WHO
report83 had guidelines, protocols, or standards that were
fully implemented. Although data are not available
specifically for sub-Saharan Africa, in 2015, globally,
75% of countries reported guidelines for dealing with
diabetes,83 so the situation has probably improved in the
region since 2010.

Financing of health care in sub-Saharan Africa
In 2014, total health expenditure in sub-Saharan Africa as
a proportion of GDP averaged 5·5% (ranging from 6·4%
in the 23 LICs, 6·0% in the three countries of lowermiddle income, 5·4% in the five countries of uppermiddle income, and 3·3% in one HIC).7,12 19 countries
were below the Chatham House recommendation of
5% of GDP spent on health.173 In the same year, average
public spending on health accounted for 42·6% of total
health expenditure.7,12 External funding ranged from

64·9% in The Gambia to 0·3% in Equatorial Guinea,
with an average of 11·2%.
In 2001, African nations adopted the Abuja
Declaration, pledging to allocate at least 15% of their
national annual budgets to health spending.174 Yet,
by 2013, only seven countries in sub-Saharan Africa—
Central African Republic, Ethiopia, Malawi, Rwanda,
Swaziland, Togo, and Uganda—had reached that
target.12 In 2014, the average out-of-pocket expenditure
as a percentage of total expenditure on health
was 34·5%, ranging from 73·5% in Sierra Leone
to 2·3% in Seychelles.7,12,172 In seven countries, out-ofpocket expenditure comprised more than 50% of the
total health expenditure (down from 12 countries
in 2010). Although unknown, we assume out-of-pocket
expenditures to be high for diabetes and often
prohibitive, producing financial barriers to access and
leading many individuals with diabetes to not seek care
(and thus avoiding short-term treatment costs but
potentially accumulating larger health deficits, leading
to even higher long-term direct costs through more
severe sequelae due to target organ damage, such as
amputations, blindness, stroke, or kidney failure, in
addition to decreased lifespan). Comorbidities and
sequelae in many instances result in catastrophic or
impoverishing health-care expenditures, sinking many
patients and their families beneath the poverty line. For
example, in a multicountry study175 that included
Tanzania, India, China, and Argentina, catastrophic
health spending related to cardiovascular events was
reported in 92% of low-income population groups, with
distress financing in 4–12% of low-income groups.
Low levels of public funding, low income levels, and
high out-of-pocket expenditures have adversely affected
the uptake and provision of care for patients with
diabetes, increasing the likelihood of long-term
complications. For example, in Malawi in 2012, families
spent 22% of their monthly per-capita budget on out-ofpocket expenditures related to NCDs.176,177 For patients
with type 1 diabetes, high out-of-pocket expenditures and
the unaffordability of care have grave consequences;
these patients have a high mortality because regular
insulin injections are not always affordable.26,149
To increase health financing for NCDs, several
countries, such as Cameroon, Botswana, and Seychelles,
have introduced earmarked taxation to influence health
behaviours, with revenues channelled to health
promotion activities. Others have launched reforms to
increase public funding for health systems and to achieve
universal health coverage, but large informal sectors
hinder effective tax collection to invest in health systems.
Against this backdrop and the competing demands of a
high burden of infectious diseases and other diseases
associated with poverty, it is highly unlikely that health
systems in sub-Saharan Africa will have adequate
financing to deal with an epidemic of diabetes and its
consequences.
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Resource management in health systems for
tackling diabetes in sub-Saharan Africa
Sub-Saharan Africa has an acute shortage of health-care
professionals; the WHO African Region accounts for
25% of the current global health workforce shortage,
expected to rise to 34% by 2035 as a result of population
growth in Africa.178 The shortage of health workers,
exacerbated by emigration,179 has constrained achieve
ment of the Millennium Development Goals in subSaharan Africa.180
There is shortage of medical graduates (more than half
of the countries in sub-Saharan Africa have only one
medical school, and 11 countries have no medical
school178,179) and nurses, whose level of training and skills
vary greatly across countries.181 More than half of countries
in sub-Saharan Africa have a category of non-physician
clinician (providers who complete an average of about
3 years of clinical training after secondary education),181
and many countries, such as Ethiopia and Malawi, have
successfully used community health workers to scale up
HIV, tuberculosis, malaria, and other essential services.182,183
These strategies should be considered for use in managing
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Figure 3: General availability of diabetes medicines in the public health
sector in 45 sub-Saharan African countries
Data are from the WHO Global Health Observatory data repository on
non-communicable-disease-related medicines and are for 2010. Data by country
can be obtained from reference 172.

Insulin (%)

Metformin (%)

Glibenclamide (%)

Hospital

48% (28–100)

49% (21–87)

65% (39–94)

Health centre

17% (0–95)

32% (8–64)

31% (11–100)

Primary health centre

12% (1–34)

31% (2–65)

48% (4–68)

Dispensary

13% (0–24)

13% (0–48)

13% (0–43)

Urban

7% (4–43)

19% (6–75)

30% (8–71)

Rural

12% (2–51)

23% (1–42)

28% (3–72)

Public

3% (2–35)

7% (1–42)

16% (3–78)

Private

11% (5–46)

33% (4–86)

39% (7–85)

Overall

13% (3–39)

22% (2–57)

32% (5–70)

Data are median (range) and are from WHO Service Availability and Readiness Assessment surveys.184 Included
countries are Benin (2013), Burkina Faso (2012), Democratic Republic of the Congo (2014), Kenya (2013), Mauritania
(2013), Sierra Leone (2012), Tanzania (2012), Uganda (2013), and Zambia (2010).

Table 4: Availability of insulin, metformin, and glibenclamide in nine sub-Saharan countries
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diabetes and other cardiovascular disease risk factors.
The scarcity of human resources affects the capacity of
health systems, and their readiness to manage diabetes is
revealed by examining WHO Service Availability and
Readiness Assessment (SARA)184 surveys for ten countries
in sub-Saharan Africa (Benin 2013, Burkina Faso 2012
and 2014, Democratic Republic of the Congo 2014,
Kenya 2013, Mauritania 2013, Togo 2012, Uganda 2013,
Tanzania 2012, Sierra Leone 2012, and Zambia 2010).
WHO SARA surveys are designed to assess the national
capacity of health systems in countries and can be applied
to assess prevention and control of NCDs by measuring
the availability of diagnostic tools, essential medications,
and trained staff at the health-care-facility level by use of
tracer conditions, such as diabetes and cardiovascular
disease.184 The methodology for the surveys is described
elsewhere.184 Findings from the country-level SARA
reports indicate that major gaps exist in front-line service
delivery. In the surveyed countries, less than half of
facilities offered diabetes management. Of the facilities
not offering diabetes services at the time of the survey,
just 40–60% demonstrated service readiness (table 3).
With the exception of Uganda, only about a third of
facilities offering diabetes services had guidelines for
treatment, and one-third or fewer had at least one
diabetes-trained member of staff. The discrepancy
between the number of trained staff and availability of
diagnostic supplies and drugs is concerning because it
is not clear how supplies and drugs are being used in
the absence of staff with formal training in diabetes
care. The availability of blood glucose testing ranged
from 14% in Burkina Faso (similar to what Beran and
colleagues185 found in Mali and Mozambique) to 80% in
Uganda, although only 31% of Uganda sites reported
the availability of diabetes-trained staff.
SARA survey data add to the findings of a literature
review (see below) to reveal the consequences of underfunded and weak health systems and years of suboptimal
investments in human resources,186 which have led to large
resource gaps for diabetes care in sub-Saharan Africa.

Availability and access to medicines for diabetes
in sub-Saharan Africa
According to WHO, essential medicines for diabetes
(metformin, glibenclamide, and insulin) were not available
in all sub-Saharan African countries in 2010 (figure 3): of
the 45 countries surveyed, metformin was available in
29 countries; glibenclamide was available in 35 countries;
insulin was available in 32 countries; and aspirin, used for
primary prevention of cardiovascular disease in patients
with diabetes, was available in 41 countries that
responded.172 In 2015, however, WHO found that, of the
countries in the WHO African region, 51% had availability
of metformin, 40% had availability of insulin, and 71% had
availability of aspirin in the public sector.83
The WHO Global Action Plan for the Prevention and
Control of NCDs 2013–20 has a target of 80% availability
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for affordable basic technologies and essential
medicines, including generic drugs, required to treat
major NCDs in both public and private facilities.187
Although reaching this target is essential if sub-Saharan
African countries are to meet the target of a 25% relative
reduction in premature mortality from NCDs by 2025,
studies reveal access challenges due to a lack of
availability and affordability of medications. For
example, studies reveal 75% median availability (actual
stocking) of insulin in the public sector (five countries)
and 46% in the private sector (six countries),149 and
challenges associated with the availability and
affordability of oral medicines.139,188–190 In 2004–13,
only eight (16·7%) countries in sub-Saharan Africa
bought insulin every year and 14 (29·2%) countries did
not buy insulin at all during this period.191
WHO SARA survey reports from 2010–13 on the
nationwide availability of insulin, metformin, and
glibenclamide for nine sub-Saharan African countries
showed the median availability of insulin to be 13%
(range 3–39; table 4). Insulin availability was generally
decreased at lower levels of the health system (ie, primary
care), with availability of 12% (2–51) in rural areas and
7% (4–43) in urban areas, and 11% (5–46) in the private
sector and 3% (2–35) in the public sector. The overall
median availability of metformin was 22% (2–57), which
also showed decreased availability at lower levels of the
health system and increased availability in rural areas
and the private sector. The findings were similar for
glibenclamide, although glibenclamide was slightly more
available in urban areas than in rural areas (table 4).184
Despite these findings, these medications are not
expensive. Management Sciences for Health (MSH)
provide international reference prices for many
medicines.192 The prices quoted by MSH are from
tenders of ministries of health and represent medicine
prices without any add-on costs at the point of entry to a
given country. Analysis of data from 1996 to 2013
suggests that the median price for insulin (a 10 mL,
100 IU/mL vial) in sub-Saharan Africa (eight countries)
was US$7·15 (range $1·52–17·58) at constant 2015
prices.193 Additionally, the median prices were $0·018
($0·002–3·304) for metformin (500 mg, ten countries);
$0·023 ($0·012–0·060) for gliclazide (80 mg, four
countries), as representative of a cheap sulfonylurea that
is suitable for patients older than 60 years; and $0·004
($0·0004–0·032) for glibenclamide (5 mg, 13 countries).192
The treatment costs, using defined daily dose,194 are
shown in table 5. These data show that treatment of
diabetes with insulin presents a significantly higher cost
to individuals than treatment with oral drugs. In addition
to purchase price, medicine costs are affected by the cost
of delivering medicines and mark-ups along the supply
chain.149 The prices shown in table 5 do not take into
account any mark-ups, such as value-added sales tax,
local taxes, international purchasing verification tax,
insurance, defence levy, overhead mark-ups, bank fees,

fees for import declaration forms and port clearance,
importer margin, handling costs, wholesale mark-ups,
retail mark-ups, health facility mark-ups, dispensing
charges, or other mark-ups within the system. The
prices also do not reflect the additional costs of ensuring
health-care personnel are adequately trained to prescribe
the treatments. Although data for these mark-ups are
scarce, particularly for insulin, the additional costs of
these taxes and levies for the other medicines have been
found to range from 18·4% to 94·4% of the final retail
price of the drug.193
These add-on costs, as well as subsidies within health
systems, mean that many factors affect the price and
affordability of insulin and that the total cost of insulin
therapy can vary from 0·2% of total GDP in South Africa
to 13·4% in Malawi.193 For example, data from four
studies done in three African countries at different
times suggested that medicine prices increased in
Mozambique (2003) and Mali (2004) between the central
government purchase price and the price paid by health
facilities to recuperate storage and transportation costs. 185
An increase in prices was not observed in Zambia and
Mozambique (2009). In Mozambique and Zambia, the
difference between the facility purchase price and the
patient purchase price was subsidised, whereas in Mali,
there was an additional mark-up, such that there was a
47% increase between the government purchase price
and the patient purchase price.
To present different prices of insulin, we combined
different data sources to show the median price (at
2015 prices) at different levels of the health system
(figure 4).193 These data show that, by comparing the
MSH prices with those obtained by different ministries
of health, many countries in sub-Saharan Africa were
purchasing insulin at the best possible price, although
there were some outliers. In some countries, insulin was
provided free-of-charge or subsidised to patients in the
public sector, whereas, in other countries, the prices were
higher but still low compared with prices in the private
sector. The prices shown in figure 4 are not affordable to
individuals in some countries—for example, at the upper
end of the scale, a 10 mL vial of insulin (100 IU/mL) cost
Annual
Cost per
costs (US$) day (US$)

Percentage of income
per day
US$1·90*

Insulin

US$3·10†

104·40

0·29

15·1%

9·2%

Metformin

26·94

0·07

3·9%

2·4%

Gliclazide

16·96

0·05

2·4%

1·5%

3·17

0·01

0·5%

0·3%

Glibenclamide

Data are median. Data come from Management Sciences for Health and authors’
calculations. Costs were calculated using defined daily dose.194 *US$1·90 is the
global poverty line, as of October 2015.4 †Used as poverty head count ratio.195

Table 5: Treatment costs for diabetes medicines and their percentage of
two different daily incomes
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US$10·88 in 2004 in the public sector in Mali or
$50·57 in 2015 in the private sector in Ethiopia.193
Data from WHO/Health Action International (HAI)190
suggest that, in some sub-Saharan African countries,
people have to pay between 0·9 and 6·7 days of wages to
afford 1 month of their diabetes treatment (figure 5).
Affordability is defined by WHO/HAI as the lowest-paid
government worker paying only 1 day’s wage for
treatment. Hence, according to the data shown in
figure 5, only glibenclamide in Ethiopia is affordable.
However, in sub-Saharan Africa many individuals do
not work in the formal sector, and hence measuring
affordability in terms of the wage of the lowest-paid
government worker is problematic, especially because
most people live on less than $1·90–3·10 per day.4 A
comparison of the annual costs of diabetes medicines
(table 5) and the daily costs of the different diabetes
treatments, using different poverty thresholds of daily

Price per vial of human insulin
(10 mL × 100IU/mL vial)

$60·00
$50·00

Maximum
Minimum
Median

$50·57

$40·00
$30·00
$20·00
$10·00
$0

$10·90
$7·77
$4·09
MSH

$14·04
$11·48
$9·75
$5·89
$2·58
$3·37
$2·30
$0
Ministry
Patient price Patient price
of Health
(public sector) (private sector)

Figure 4: Price per vial of insulin at different levels of the health system
Prices (standardised to 2015 US$) of a vial of human insulin (10 mL, 100 IU/mL
vial) reported by 18 sub-Saharan-African countries. Prices differed in both the
public and private sectors depending on whether the vials were purchased from
primary care centres, retail pharmacies, or hospitals. Procurement prices
obtained by MSH are also shown. Data are from ACCISS Study Insulin Price
Profile 2016.193 MSH=Management Sciences for Health.
Metformin 500 mg
Glibenclamide 5 mg

Ethiopia

Kenya

Nigeria

Tanzania
0
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Number of day’s wages needed to pay for 1 month of treatment

Figure 5: Affordability of oral drugs for diabetes care in day’s wages for the
lowest-paid government worker in four countries in sub-Saharan Africa
Affordability was measured in the number of day’s wages that the lowest-paid
government worker needed to pay for 1 month of treatment of metformin or
glibenclamide in 2004. Data are from the WHO/Health Action International
database of medicine prices.190
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income, shows that daily drug costs (ministry of health
purchase prices and not retail price) represent
0·5–15·1% of income for someone with diabetes living
on $1·90 per day.

Health service delivery for diabetes in
sub-Saharan Africa

Analysis of Service Delivery Indicator surveys
To identify service delivery gaps in diabetes care we
analysed data from Service Delivery Indicator (SDI)
surveys done in four sub-Saharan African countries by
the World Bank, in cooperation with the African
Economic Research Consortium and the African
Development Bank.138 The SDI surveys include data at
the level of the health facility on expenditures, provider
effort (absence rate, caseload per provider), provider
knowledge and ability (diagnostic accuracy, adherence to
clinical guidelines, and management of maternal and
neonatal complications), and inputs (availability of
supplies, equipment, and drugs). Diagnostic accuracy is
measured through patient case simulations (vignettes)
for seven tracer conditions: malaria with anaemia,
diarrhoea with severe dehydration, pneumonia, diabetes,
pulmonary tuberculosis, postpartum haemorrhage, and
neonatal asphyxia.
The SDI surveys are complementary to and build on
surveys (eg, WHO SARA surveys) that focus on the
availability of resources and health system readiness for
service provision, including for NCDs. Our analysis of
SDI surveys broadens and deepens our understanding of
service delivery and the quality of diabetes care in subSaharan Africa by providing insights into the knowledge,
ability, and effort of providers (technical quality), and the
availability of important inputs, such as drugs,
equipment, and infrastructure (structural quality; see
appendix 1 for additional information and methods).
We investigated the four publicly available SDI
surveys: Kenya (2012), Nigeria (2013), Tanzania (2014),
and Uganda (2013). When presented with vignettes, less
than 53% of the sampled providers in all countries
could accurately diagnose diabetes, with the exception
of Kenya where 81% of providers gave the correct
diagnosis (weighted results; figure 6A). Conversely, in
all countries except Nigeria, more than 80% of providers
could diagnose tuberculosis, with the proportion as
high as 98% in Kenya and 92% in Tanzania (figure 6A).
Only 4% of the sample could correctly diagnose all
seven conditions. The proportion of providers able to
identify all seven conditions was highest in Kenya,
where almost 17% of the surveyed providers correctly
diagnosed all conditions presented during the patient
simulation.
Although the average clinical guideline score—
indicating the degree of adherence to diabetes clinical
guidelines—was less than 30% in all countries, we
observed a wide range of performance scores within
countries, with some providers performing all necessary
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tasks in the domains of the score (symptom, patient,
history, and physical examination; figure 6B).
More than half of providers who correctly diagnosed
diabetes could not prescribe the appropriate treatment,
with the exception of Tanzania, where 89% of the
providers who correctly diagnosed diabetes prescribed
oral hypoglycaemics (figure 6C). In addition, 77% of
providers in Kenya who correctly diagnosed diabetes
indicated that they would refer to higher-level facilities.
In other countries, this share ranged from 34% to 47% of
providers. Whether this pattern of referral is due to a lack
of knowledge or confidence in applying the knowledge is
not known. However, as the number of diagnosed
patients increases, referring the majority to higher-level
facilities is unlikely to be a sustainable option.
To investigate the association between provider and
facility characteristics and the provider’s ability to correctly
diagnose diabetes, we did a logistic regression analysis.
Table 6 shows a summary of the analytic sample of
provider and facility characteristics in these countries. The
total sample consisted of 6146 providers, with the largest
number of providers coming from Nigeria. With the
exception of Tanzania, nurses, midwives, and community
health workers represented more than half of the sampled
providers. In Tanzania, 75% of the sample consisted of
physicians and medical or clinical officers. In Nigeria,
physicians represented only 10% of the sample, whereas
nurses, midwives, and community health workers
represented 82% of the sample (predominantly
community health workers). In Kenya, Nigeria, and
Uganda, most of the sampled providers were female.
The facility statistics in table 6 show that most providers
in all countries were employed at lower-level facilities
(eg, dispensaries or health centres) and, except for
Tanzania, were primarily located in rural areas. Generally,
providers worked at facilities with a high equipment
index, suggesting that they had access to a thermometer,
adult weighing scale, sphygmomanometer, and
stethoscope. In Nigeria and Uganda, however, more than
a third of providers did not have access to all four pieces
of equipment.
Table 7 shows the logistic regression results of the factors
associated with a provider’s ability to diagnose diabetes.
Female providers had significantly lower odds than male
providers of correctly diagnosing diabetes in Kenya (odds
ratio [OR] 0·58, 95% CI 0·35–0·98) and Nigeria (0·73,
0·61–0·86), but we cannot explain the reasons behind this
difference. Compared with the highest cadre category
(physicians, medical officers, and clinical officers), lower
cadres had significantly lower odds of diagnosing diabetes
in most countries. This result suggests that there is room
for improvement in training of lower cadres of health
providers in diagnosing diabetes.
It is encouraging that geographical location was not a
significant predictor in any of the four countries, with
providers in rural areas not having statistically lower odds
of diagnosing diabetes than those in urban areas. We did

Oral hypoglycaemics
Insulin only when oral hypoglycaemics are not effective
Follow-up at a specialist diabetes clinic or higher-level facility

80

89

77

60
50
40

47
34 35 36

18

20
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6
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41

39

Kenya

Nigeria

Tanzania
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Figure 6: Measures of health service delivery for diabetes in sub-Saharan Africa
Data are from Service Delivery Indicator surveys from four countries: Kenya (2012), Nigeria (2013), Tanzania
(2014), and Uganda (2013). The number of providers in each country is shown in table 6. For weighting of the
data, see reference 196. (A) Share of providers correctly diagnosing each patient simulation vignette by country.
(B) Box plot of clinical guideline scores by country; boxes are shown as median and IQR; the dots show outliers and
the red line indicates 50%. (C) Treatment prescribed by providers who correctly diagnosed diabetes.
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not find a statistically significant association between the
ability of providers to diagnose diabetes and whether the
facility was public in all countries studied. Interestingly, in
Kenya and Nigeria, a higher equipment index (table 6) was
found to significantly increase the odds of correctly
diagnosing diabetes. Although the availability of a
glucometer was not generally recorded in the SDI surveys,
good availability of the other equipment might be
reflective of the availability of a glucometer and hence an
increased ability to diagnose diabetes. As mentioned
earlier, the variation in the equipment index was quite low,
with most providers having access to the basic equipment
(particularly in Kenya); thus, the significant ORs suggest
that ensuring universal availability of basic equipment
could substantially improve diagnostic accuracy.
Table 8 shows the ordinary least squares regression
results of the factors associated with higher clinical
guideline scores. The dependent variable was the logtransformed clinical guideline score. The results were
consistent with the findings for diagnostic accuracy
(table 7). Providers in lower cadres were less likely to
have high clinical guideline scores than providers in
higher cadres. Nurses, midwives, and community health
workers were found to have 10–45% lower clinical
guideline scores than physicians and medical and clinical
officers. In Nigeria and Tanzania, providers at district
hospitals were found to have a 45% and 42%, respectively,
higher clinical guideline score than providers at the
Kenya
(n=526)

Nigeria
(n=4388)

Tanzania
(n=498)

Uganda
(n=684)

Provider characteristics
Cadre
Physicians/medical officers
Nurses/midwives
Community health workers
Other
Provider is female

241 (46%)

456 (10%)

371 (75%)

146 (21%)

22 (4%)

859 (20%)

127 (25%)

520 (76%)

240 (46%)

2705 (62%)

NA

NA

23 (4%)

368 (8%)

NA

320 (61%)

2721 (62%)

199 (40%)

417 (61%)

431 (82%)

1492 (34%)

194 (39%)

322 (47%)

18 (3%)

Provider performance
Correctly diagnosed diabetes
Clinical guideline score*

0·28 (0·16)

0·20 (0·17)

0·24 (0·14)

0·12 (0·09)

Facility characteristics
Facility type
Dispensary

138 (26%)

299 (7%)

306 (62%)

382 (56%)

Health centre

290 (55%)

3285 (75%)

124 (25%)

284 (41%)

98 (19%)

804 (18%)

68 (14%)

18 (3%)

Rural

District hospital

363 (69%)

2413 (55%)

249 (50%)

534 (78%)

Public

331 (63%)

4212 (96%)

339 (68%)

465 (68%)

Equipment index†

0·97 (0·10)

0·77 (0·32)

0·95 (0·13)

0·79 (0·27)

Data are n (%) or mean (SD). The total sample consisted of 6146 providers, of whom 6096 were analysed. NA=not
applicable.*The clinical guideline score was calculated as the share of all tasks expected to be done (eg, patient history,
symptoms, physical examination) when a patient presents with diabetes symptoms. †The equipment index was
calculated as the share of four essential pieces of equipment available and functioning at facilities:
sphygmomanometer, thermometer, stethoscope, and weighing scale.

Table 6: Summary statistics of the analytic sample of the Service Delivery Indicator surveys from
Kenya (2012), Nigeria (2013), Tanzania (2014), and Uganda (2013)

644

lowest level facilities. The equipment index was also
positively associated with the clinical guideline score in
Nigeria and Uganda.
The analyses of service delivery indicators suggest that,
in the countries studied, there is low readiness across all
levels of care and cadres of health professionals in
management of diabetes in terms of correct diagnosis,
adherence to guidelines, and provision of appropriate
treatment. This finding suggests that lower levels of care
are unprepared for diabetes diagnosis and treatment,
which has implications for development and scaling up of
community-based or primary health care-based diabetes
management programmes in sub-Saharan Africa.

Implications of health system responsiveness to
diabetes in sub-Saharan Africa
The findings from WHO SARA surveys and World Bank
SDI surveys revealed that health systems in sub-Saharan
Africa are unprepared for delivery of effective health
services for patients with diabetes. However, a
comprehensive understanding of how resource and
service gaps in health systems affect demand, and how
the interaction of supply-side gaps and demand-side
dynamics translate into unmet need in sub-Saharan
Africa, is constrained by scarce data. In the next section,
we analyse surveys of 12 sub-Saharan African countries
to examine the nature and extent of unmet need at each
crucial stage of the diabetes care process.

Analysis of unmet need and the cascade of care
for diabetes in sub-Saharan Africa
One innovative analytical approach to assess health
system performance is the construction of a cascade of
care with a tracer condition. Cascade-of-care analysis
involves quantitative depiction of the step-wise care for
the population affected by a disease of interest,
including screening, diagnosis, linkage to treatment
programmes, adherence to treatment, and finally
achievement and maintenance of control. This analysis
depicts the dynamics between demand and health
system responses at each step of the care continuum
and provides the opportunity to identify areas of unmet
need and where attrition in care occurs.11
Cascade-of-care analysis has been used to monitor
progress towards coverage goals for populations affected
by HIV/AIDS.197,198 In the USA, 2007–12 data from the
National Health and Nutrition Examination Survey
(NHANES) have been used to construct a cascade of care
for diabetes to show that nearly a third of patients with
diabetes are unaware of their diagnosis, and that those
who are undiagnosed are less likely than those with a
diagnosis to achieve health targets for multiple chronic
diseases.199
We used individual-level data from population-based
surveys done between 2005 and 2013 in 12 sub-Saharan
African countries to assess unmet need for care and the
care cascade for diabetes. WHO STEPS survey data were
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available for ten countries: Benin, Comoros, Guinea,
Kenya, Liberia, Mozambique, Seychelles, Tanzania, Togo,
and Uganda. The STEPS survey is a standardised
approach to collecting data about cardiovascular NCDs
from adults aged 25–64 years in WHO member countries.
Briefly, the STEPS surveys include collection of
demographic data (step 1); physical measurements such
as blood pressure and BMI (step 2); and biochemical
measurements, including fasting plasma glucose
(step 3).200 Further details about the STEPS instrument
are provided elsewhere.5 Given that a standardised
approach is used in all countries, data from the STEPS
surveys can be used to compare epidemiology and healthsystem performance across countries.
We supplemented data from STEPS surveys with
information from the Demographic and Health Survey
for Namibia (2013),201 which, similar to STEPS surveys,
includes both fasting plasma glucose measurements and
self-reported data about access to diagnosis and treatment
for diabetes. For South Africa, we used the 2013 South
Africa Nutrition and Health Examination Survey
(SANHANES), a nationally representative cross-sectional
health and nutrition study led by the South African
Human Sciences Research Council.202 Together, the
STEPS, Demographic and Health, and SANHANES
surveys consisted of 38 311 individuals across 12 countries
over the period of 2005–15. How we pooled individual
data from different datasets to enable comparability is
described in the appendix 1. In panel 5 we briefly describe
the approach used to define diabetes and the method
used to construct the care cascade. The methods used to
pool data from different surveys, construct the care
cascade, and identify unmet need, as well as the
limitations of that analysis, are described in detail
elsewhere.11
The diabetes care cascade across all countries is shown
in figure 7. The first step in the cascade is receipt of a
diagnostic test, specifically a blood glucose measurement.
This initial diagnostic test was associated with the
greatest loss to care in all countries, with an average loss
to care of 50% (range 23–81). Among the group who selfreported having received a glucose measurement, the
cascade shows that, on average, 13% (0–26) of the total
population with diabetes was then lost to follow-up at the
stage of being told about their diagnosis by a health-care
provider (figure 7). Among those who reported
completing the first two steps in the cascade, an
additional 20% (5–31) of the total population with
diabetes was lost to care and follow-up at the stage of
receiving advice on lifestyle modification. Finally, a
further 6% (3–10) of the total population with diabetes
was lost to care between the stages of receiving advice
and receiving any medication, including oral medication
or insulin, for diabetes control. Overall, the analysis of
the data from the 12 countries showed that the average
percentage of the population with diabetes who
completed the care cascade was 11%, with a range of 7–33.

Kenya (n=526)

Nigeria (n=4388)

Tanzania (n=498) Uganda (n=684)

Ref

Ref

Provider characteristics
Provider’s age
<30 years
30–59 years
>60 years
Provider is female

Ref
1·73* (1·10–2·74)
NA
0·58* (0·35–0·98)

0·77* (0·62–0·95)

1·30 (0·66–2·65)

1·99 (0·96–4·13)

1·50 (0·52–4·31)

0·73† (0·61–0·86)

0·67 (0·43–1·05)

Ref
0·83 (0·60–1·15)
NA
0·85 (0·57–1·26)

Cadre
Physician/
medical officer‡

Ref

Ref

Ref

Nurse/midwife

1·31 (0·48–3·59)

0·68* (0·50–0·94)

Community
health worker

0·53* (0·29–0·95)

0·56 (0·32–1·01)

0·25† (0·18–0·34)

NA

Other§

0·64 (0·20–2·01)

0·32† (0·22–0·47)

NA

Ref
0·18† (0·11–0·31)
NA
0·19† (0·06–0·64)

Facility characteristics
Facility type
Dispensary

Ref

Ref

Ref

Ref

Health centre

0·80 (0·44–1·46)

0·71* (0·50–1·00)

1·64 (0·97–2·76)

2·26† (1·57–3·26)

District hospital

1·21 (0·48–3·06)

1·57* (1·04–2·37)

3·08† (1·53–6·19)

2·45 (0·78–7·67)

Location
Urban
Rural

Ref

Ref

Ref

Ref

0·94 (0·52–1·70)

0·84 (0·70–1·00)

0·92 (0·57–1·47)

Facility is public

0·68 (0·41–1·15)

1·47 (0·92–2·35)

0·81 (0·49–1·33)

0·64 (0·39–1·03)
1·32 (0·88–1·98)

Equipment index¶

8·10† (1·68–39·10)

1·51† (1·12–2·03)

5·70 (0·78–41·77)

2·28 (0·99–5·28)

Data analysed were from Service Delivery Indicator surveys from Kenya (2012), Nigeria (2013), Tanzania (2014),
and Uganda (2013). Data are odds ratio (95% CI). Binary-dependent variable was equal to 1 if a provider correctly
diagnosed diabetes during the patient simulation vignette, 0 otherwise. NA=not applicable. *p≤0·05. †p≤0·01. ‡Also
includes clinical officers. §Includes paraprofessionals and lab technicians. ¶Equipment index was calculated as the share
of four essential equipment available and functioning at the facilities: sphygmomanometer, thermometer,
stethoscope, and weighing scale.

Table 7: Logistic regression results of the determinants of a provider’s ability to diagnose diabetes

The care cascades for three exemplar countries
(Mozambique, Kenya, and South Africa) are shown in
the appendix 1. These three countries were chosen as
examples because they represent three very different
levels of wealth, as measured by GDP per capita in 2011
international dollars for the year of the survey
(Mozambique [2005]: Intl$735, Kenya [2015]: $2818,
South Africa [2013]: $12 375).
Our analysis shows unmet need at every step of the
diabetes care continuum, which leaves around 50% of
patients with diabetes going undiagnosed and further
substantial dropoffs in care throughout the remainder of
the cascade. From this analysis, and what is known about
unmet need in the region, we surmise that for people
diagnosed with or at risk of diabetes, health systems are
unable to provide the needed services, with most patients
not receiving the necessary advice and medication.
Unmet need and suboptimal care mean that patients will
probably have delayed presentation to the health system
and receive advice and medication late in the care
process. Delayed presentation and treatment have
adverse effects on health outcomes in diabetes, leading to
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Kenya
(n=526)

Nigeria
(n=4438)

Tanzania
(n=498)

Uganda
(n=684)

Ref

Ref

Provider characteristics
Provider’s age
<30 years

Ref

Ref

30–59 years

–0·06 (0·06)

–0·11*(0·05)

0·04 (0·10)

>60 years

NA

–0·07 (0·13)

–0·15 (0·19)

NA

–0·10 (0·11)

–0·35† (0·01)

–0·04 (0·07)

–0·21† (0·07)
Ref

Provider is female

0·05 (0·07)

Cadre
Physician/medical officer‡

Ref

Ref

Ref

Nurse/midwife

–0·10 (0·11)

–0·30† (0·08)

–0·21* (0·08)

–0·45† (0·09)

Community health worker

–0·24† (0·08)

–0·34†(0·08)

NA

NA

Other§

–0·35 (0·27)

–0·41† (0·10)

NA

–0·15 (0·18)

Ref

Ref

Ref

Ref

Facility characteristics
Facility type
Dispensary
Health centre
District hospital

0·01 (0·10)

0·08 (0·09)

0·28† (0·08)

0·29† (0·08)

–0·07 (0·13)

0·45† (0·11)

0·42† (0·12)

0·17 (0·21)

Location
Urban

Ref

Rural

–0·18* (0·08)

Ref
0·04 (0·04)

Ref
–0·08 (0·08)

Ref
0·02 (0·09)

Facility is public

0·10 (0·08)

0·03 (0·11)

0·00 (0·08)

0·02 (0·09)

Equipment index¶

0·59 (0·35)

0·19* (0·07)

–0·02 (0·25)

0·34* (0·15)

Data analysed were from Service Delivery Indicator surveys from Kenya (2012), Nigeria (2013), Tanzania (2014), and
Uganda (2013). Data are coefficients from ordinary least squares regressions, with the log(clinical guidelines score) as the
dependent variable and robust SEs in parentheses. The clinical guideline score was calculated as the share of all tasks
expected to be done (eg, patient history, symptoms, physical exam) when a patient presents with diabetes symptoms.
NA=not applicable. *p≤0·05. †p≤0·01. ‡Also includes clinical officers. §Includes paraprofessionals and lab technicians.
¶Equipment index was calculated as the share of four essential equipment available and functioning at facilities:
sphygmomanometer, thermometer, stethoscope, and weighing scale.

Table 8: Ordinary least squares regression results with the log of the clinical guideline score as the
dependent variable

difficulties for patients and their families due to ill health
and to adverse economic consequences for patients, their
families, and their countries.

Economic consequences of diabetes in
sub-Saharan Africa
Economic burden of diabetes to individuals

In addition to ill health and substantial reductions in
quality of life, diabetes imposes a non-negligible financial
burden on affected individuals, families, and societies.
While patients with diabetes face direct costs of illness
through medical treatment of the disease and its
comorbidities and sequelae, they also experience income
losses through reduced productivity and disability, which
means inability to work in severe cases.
The relatively high prices for necessary health items,
such as blood glucose strips and insulin, impose a
considerable financial burden on individuals, as discussed
in previous sections of this report. Combined with the
substantial reliance of health systems in sub-Saharan
Africa on out-of-pocket expenditure, patients with diabetes
in the region often have only limited access to adequate
and timely treatment, potentially resulting in an increased
646

risk of diabetes-related health complications. Moreover,
comorbidities and target organ damage due to diabetes
might cause catastrophic health-care expenditures,
shifting many patients and their families beneath the
poverty line.203 Simultaneously, these adverse effects are
likely to be perpetuated in the absence of adequate social
security systems; families might attempt to offset such
catastrophic expenditures by putting children into the
workforce, thus cutting short their education and reducing
their future prospects of financial wellbeing.
Measurement of the direct economic burden on
individuals is complicated by the fact that health
expenditure for diabetes-related complications is difficult
to quantify because diabetes might not be the only
attributable cause. The IDF therefore derives estimates
for direct costs of diabetes from each country’s total
health expenditure, applying age-specific and sex-specific
ratios of average heath expenditure to people with and
without diabetes. Accordingly, estimated per-patient
expenditures for diabetes in 2015 in sub-Saharan Africa
ranged between US$243 and $419,25 although the validity
of these numbers is unknown because cost ratios were
based on US data. A 2017 study204 that used a similar
approach but different cost ratios for LMICs found
average per-patient costs of $580. Other studies estimated
direct costs of diabetes per person each year to be $138 in
Tanzania in 1989–90,205 and $489 in Cameroon in 2001.206
Although not all of these expenditures are borne by
individuals directly through out-of-pocket payments,
increased insurance contributions and taxes can serve to
further burden individuals.
Indirect costs of illness result from productivity losses of
workers during their productive years (because costs of
early mortality are not borne by patients themselves, we do
not consider this position in this section). These
productivity losses comprise absenteeism (sick workers
failing to appear for work), presenteeism (unfit workers
coming to work but not performing to full capacity), and
labour-force dropout (panel 6). Notably, whereas in HICs
productivity losses might be partially or fully offset by
social security systems (eg, continued pay during sick
leave, insurance payments in case of permanent disability),
in sub-Saharan Africa productivity losses are likely to fully
accrue at the level of the sick individual through foregone
wages from formal or informal work and reduced
agricultural yield in the case of subsistence farmers.

Economic burden of diabetes to countries
Evidence about the total economic burden of diabetes to
societies in sub-Saharan Africa is scarce. Kirigia and
colleagues215 estimated that the combined direct and
indirect costs amounted to Intl$25·51 billion (2005
purchasing power parity) in 2000, but they might not
have captured the full picture because diabetes-related
complications were excluded from their analysis. We
therefore based our evaluation of economic burden to
countries on a top-down approach used in a study by
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Bommer and colleagues.204 Analysing direct health
expenditure and indirect costs of diabetes, that study
estimated the global economic burden in adults in 2015
to be US$1·31 trillion, equivalent to 1·8% of global GDP.
Using prevalence and mortality data from the IDF
Diabetes Atlas,25 the study204 estimated direct costs based
on countries’ per-capita health expenditure, assuming
literature-derived ratios between age-specific and sexspecific treatment costs for people with and without
diabetes. These ratios varied between HICs and LMICs,
between women and men in HICs, between rural and
urban areas in LMICs, and between people with
diagnosed versus undiagnosed diabetes, thus extending
previous work by the IDF.25 Note, however, that no
appropriate studies for sub-Saharan Africa could be
identified, and thus the applied cost ratios might not
fully reflect the situation in the region. Indirect costs
were defined as productivity losses due to mortality or
disability, as measured by foregone labour earnings. As
wage data from sub-Saharan African countries are scarce,
labour earnings were proxied by the labour income share
in GDP per working age person, as measured in
2015 US$. A more detailed discussion of the method is
provided elsewhere204 and in the appendix 1.
Based on the same approach as that used by Bommer
and colleagues,204 and using national account data from
the World Development Indicators database12 for
47 countries in sub-Saharan Africa, we estimated the
overall costs of diabetes in 2015 for sub-Saharan Africa to
be US$19·45 billion, or 1·2% of cumulative GDP of the
entire region. About $8·64 billion (44·4%) of this burden
arose from indirect costs. About $12·10 billion (62·2%)
arose from southern Africa, mainly from the relatively
wealthy South Africa, and only $1·70 billion (8·7%) arose
from western Africa. The share of indirect costs by region
varied from 23·2% to 49·2% (figure 8).
Productivity losses consisted of four components:
premature mortality, which amounted to $7·86 billion
(91·0%) of total indirect costs; diabetes-related
complications and malaise, leading to workforce dropout,
which accounted for $0·53 billion (6·2%) of total indirect
costs); sick leave (absenteeism), which accounted for
$0·17 billion (1·9%) of total indirect costs; and decreased
productivity while working (presenteeism), which
amounted to $0·07 billion (0·9%) of total indirect costs
(figure 9). These estimates provide important
benchmarks for the economic value that could be
generated through improvements in initiatives to address
diabetes risk factors, prevention, and early diagnosis.
An important question for policy makers in subSaharan Africa is how the economic costs of diabetes are
going to evolve in the short and medium term. To predict
economic costs of diabetes over time, we followed
previous projection attempts by the IDF25 by using
quinquennial UN Population Prospects data for the
years 2015–30 (using the medium variant provided by the
UN Population Division),216 as well as projected

urbanisation rates from the UN.217 Both demographic
changes and urbanisation rates are likely to be substantial
drivers of future costs because an urban sedentary
lifestyle is considered an important risk factor for
diabetes.218 Our projected economic costs also take into
consideration real GDP and GDP per-capita growth
(extrapolated based on past growth rates obtained from
the World Bank).12
Panel 5: Constructing the diabetes care cascade
When constructing the diabetes care cascade, diabetes was defined based on the current
WHO and American Diabetes Association diagnostic criteria as a fasting plasma glucose
concentration of more than or equal to 7·0 mmol/L (126 mg/dL), a 2 h plasma glucose
concentration of more than or equal to 11·1 mmol/L (200 mg/dL), or a HbA1c
measurement of 6·5% (48 mmol/mol) or higher.136,137 This definition represents the goldstandard clinical practice guidelines that are being used internationally. The data had one
or more of these measures for each individual surveyed (appendix 1).
Those individuals reporting use of medication for diabetes were also classified as having
diabetes, irrespective of the biomarker values. Respondents who self-reported a diagnosis
of diabetes, but were not on medication and lacked the criteria indicated above, were not
classified as diabetic. Additionally, we quantified met need for four different metrics of
diabetes care in the population with diabetes: ever having received a blood glucose
measurement as a measure of diagnosis (before the STEPS or other survey with which the
diagnosis was made); for those who had received a blood glucose measurement, ever
having been told about the diagnosis of diabetes as a measure of awareness of diagnosis;
receipt of any advice from a health-care provider to lose weight or exercise; and use of
either oral medications or insulin for treatment of diabetes.
Using these metrics, we constructed a diabetes care cascade for each of the 12 countries
for which data were available. This cascade, created with individual-level data, shows the
percentage of the total population with diabetes that self-reported reaching each
subsequent step in the care process, conditional on having reached the previous step.

100%

–50 percentage
points

50%

–13 percentage
points
37%

–20 percentage
points
–6 percentage
points
17%

Total people
with diabetes

Glucose measured

Aware of diagnosis

Advice received

11%

Medication
received

Figure 7: Cascade of care for diabetes based on population survey data from 12 sub-Saharan African countries
(2005–15)
This figure depicts the diabetes cascade of care based on data from 10 STEPS surveys (Benin, Comoros, Guinea,
Kenya, Liberia, Mozambique, Seychelles, Tanzania, Togo, and Uganda), the Namibia Demographic and Health
Survey, and the South Africa Nutrition and Health Examination Survey. All surveys were done during the period
from 2005 to 2015. By use of individual-level data from these surveys, we created a diabetes care cascade, which
shows the percentage of the total population with diabetes that self-reported reaching each subsequent step in
the care process, conditional on having reached the previous step. See Panel 5 on how diabetes was defined. All
numbers displayed represent the percentage of the total number of people with diabetes in the sample.
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Panel 6: Labour-market effects of diabetes
Based on a systematic review and assessment of the available
empirical evidence on the labour-market effects of diabetes, a
global cost-of-illness study204 estimated that the reduction in
labour-force participation of individuals with diabetes in
high-income countries (HICs) was 12·6% for men and
25·2% for women. Conversely, in low-income and
middle-income countries (LMICs), reduction in labour-force
participation ranged from 1·1% to 13·2% for men and
from 1·2% to 17·4% for women. Moreover, in high-income
settings, men and women with diabetes who were in the
labour force were found to be absent from work for 1·9–4·3
additional days per year, whereas the corresponding numbers
in LMICs ranged from 1·9 to 8·6 excess days for men and
from 2·8 to 10·2 excess days for women. Finally, productivity
losses while at work (presenteeism) in people with diabetes
were found to be 0·3% in HICs and 0·6–1·0% in LMICs.
The underlying empirical evidence largely draws on data from
HICs and upper-middle-income countries. Effects on labourmarket dropout and presenteeism are based on studies from
the USA207,208 and Mexico.209,210 Although the diversity of
sources is larger for absenteeism—with studies from the
USA,211 Mexico,210 India,212 Iran,213 and Namibia214—it is unclear
to what extent these labour-market effects accurately capture
the situation in sub-Saharan Africa. For instance, the
combination of limited capabilities for management of blood
sugar levels and a shortage of preventive treatment is likely
to lead to high rates of severe complications in the long term,
hence potentially increasing the rate of labour-force dropout.

Southern Africa

12·10 (49·2%)

Western Africa

Direct costs
Indirect costs

1·70 (23·2%)
3·82 (39·7%)

Eastern Africa

1·83 (42·2%)

Middle Africa
All sub-Saharan
Africa

19·45 (44·4%)
0

10

20
30
Economic costs in billion US$

40

Figure 8: Economic burden of diabetes in sub-Saharan Africa (2015)
Numbers in parentheses are percentages of indirect costs in total costs. Data are
from the World Development Indicators database12 and are for 47 countries in
sub-Saharan Africa. Estimates for southern Africa include Botswana, Lesotho,
Namibia, South Africa, and Swaziland. Estimates for western Africa include
Benin, Burkina Faso, Cape Verde, Côte d’Ivoire, The Gambia, Ghana, Guinea,
Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone,
and Togo. Estimates for eastern Africa include Burundi, Comoros, Eritrea,
Ethiopia, Kenya, Madagascar, Malawi, Mauritius, Mozambique, Rwanda,
Seychelles, South Sudan, Sudan, Tanzania, Uganda, Zambia, and Zimbabwe.
Estimates for middle Africa include Angola, Cameroon, Central African Republic,
Chad, Democratic Republic of the Congo, Republic of the Congo,
Equatorial Guinea, Gabon, and São Tomé and Príncipe.
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We considered three scenarios for the evolution of agegroup-specific and sex-specific diabetes prevalence and
mortality. First, we used the optimistic assumption that
age-group-specific and sex-specific diabetes mortality
and prevalence stay constant over time (scenario A).
Second, we let the age-group-specific and sex-specific
diabetes prevalence and mortality increase, depending
on a country’s income-group classification according to
the World Bank and adult diabetes prevalence in 2015, as
shown in table 9 (scenario B). The rationale for this
approach was the assumption that middle-income
countries will increasingly adopt western sedentary
lifestyles and consumption patterns. This trend is likely
to be less pronounced in LICs where restricted
household budgets constrain rapid changes in
consumption patterns. Third, in scenario C, we doubled
all growth rates from scenario B. Thus, our projections
cover very optimistic to very pessimistic outlooks.
In addition to changes in prevalence and mortality, the
growth of direct costs depends in part on remuneration of
health personnel; Organisation for Economic Cooperation and Development data suggested that
compensation of health workers accounted for up to 57%
of total health expenditure during the past decade, and we
assumed sub-Saharan African health sectors to be
particularly labour intensive.219 Similarly, the increase in
indirect costs depends on the evolution of average annual
wages. For all projection scenarios, we assumed that both
average wages and the remuneration of health personnel
grow at the same rate as real GDP per capita.
Our estimates suggest that the economic costs of
diabetes for sub-Saharan Africa will increase from
US$19·45 billion (1·2% of GDP) in 2015 to $35·33 billion
(1·1% of GDP) in 2030, according to scenario A; to $47·33
billion (1·4% of GDP) in 2030, according to scenario B;
and to $59·32 billion (1·8% of GDP) in 2030, according
to scenario C (measured in 2015 prices; figure 10).
While all projection scenarios place southern Africa on
top, with an increase from US$12·10 billion in 2015 to
$17·15–$29·20 billion in 2030 depending on the scenario,
we also predict substantial growth in absolute costs in
eastern Africa (from $3·82 billion in 2015 to up to
$16·21 billion in 2030 for scenario C; figure 10). Relative
to GDP, southern Africa is again predicted to bear the
largest economic burden in all projection scenarios
(from 3·5% in 2015 to between 3·4% for scenario A and
5·8% for scenario C in 2030; figure 10).
Despite uncertainties about the future evolution of
diabetes prevalence and diabetes-related mortality, and
future GDP growth, the numbers are alarming. The
high direct and indirect economic burden sub-Saharan
Africa is predicted to face creates a strong incentive for
policy makers to increase efforts to prevent diabetes and
reduce diabetes-related complications and premature
mortality. However, as the analysis in this report shows,
health systems in sub-Saharan African countries are illprepared to effectively manage diabetes; the existing
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health-systems response is weak, the care provided is
suboptimal, and the unmet need is very large. If diabetes
is effectively managed, its future health and economic
burden could be substantially reduced. The following
sections therefore point to potential health policies that
might help sub-Saharan African countries to better cope
with the challenges imposed by diabetes, and discuss the
potential benefits that could be realised if diabetes in
sub-Saharan Africa was to be managed according to
international guidelines and evidence.

Benefits of scaling up diabetes interventions in
sub-Saharan Africa
For people with diabetes, the three principal coexisting
risk factors leading to morbidity and mortality are high
blood pressure, disordered lipid profile, and poor
glycaemic control; an aim of good diabetes care is to
prevent their long-term complications. Although all three
risk factors have been associated with macrovascular and
microvascular complications, substantial differences exist
in their relative effects, in terms of the complexity of their
treatment and monitoring regimens, their therapeutic
window, and the costs of therapy. Important interactions
exist between these risk factors for both macrovascular
(coronary heart disease, stroke) and microvascular
(retinal, renal, neuropathic) complications of diabetes,220,221
with treatment guidelines emphasising the importance of
addressing all three.222
For both blood pressure and lipid therapies, there has
been a move towards targeting treatment to individuals
at increased levels of risk, rather than according to levels
of blood pressure or lipids, with the understanding that
different individuals might experience different benefits
and risks from therapy depending on their comorbid
conditions. For example, people with previous
myocardial infarction or stroke might benefit from
initiation of treatment at lower levels of blood pressure
or LDL-cholesterol than those who have not had a
previous cardiovascular event. The risk-based approach
to treating blood pressure, termed benefit-based tailored
treatment (BTT), has been shown to be more effective
and less costly than treating blood pressure to target
levels (the so-called treat-to-target [TTT] strategy).223
Additionally, when considering blood pressure, lipid,
and glycaemic control in patients with diabetes, in
countries with poor insulin availability (eg, many
LMICs), BTT was shown to be more clinically effective
and cost-effective than TTT for preventing microvascular
and macrovascular complications. When insulin was
available, the BTT strategy was no longer superior to the
TTT strategy for preventing microvascular disease.152
Using the same model as used in our previous study,152
we tested, with a microsimulation model, whether a BTT
approach compared with the status quo (ie, currently
received care) or a TTT approach compared with the
status quo would be beneficial to people with diabetes in
countries in sub-Saharan Africa for overall management

of diabetes risk factors. A summary of the methods is
shown in panel 7. We found that, from a population
perspective, a BTT strategy would be more effective and
cost-effective than a TTT strategy (table 10). Although a
similar proportion of people with diabetes would typically
be recommended treatment of any kind (for example, a
mean of 86·4% under the TTT strategy vs 88·4% under
the BTT strategy in Malawi; table 10), those typically
treated with the BTT strategy would be treated more
intensively (for example, 4·5 vs 3·5 medications per
person in Malawi; table 10).
Compared with the TTT strategy, the BTT strategy
would recommend significantly more adults with
diabetes to receive blood-pressure-lowering drugs and
would non-significantly increase the number of patients
treated with statins and glucose-lowering therapies
(table 10). Additionally, the BTT strategy was estimated to
avert two-to-four times as many macrovascular events
(myocardial infarction and stroke) as the TTT strategy
over a period of 10 years, although the number of
microvascular events did not significantly differ between
the two strategies.

6·2% ($0·53 bn)

0·9% ($0·07 bn)
1·9% ($0·17 bn)

91·0% ($7·86 bn)

Mortality
Presenteeism
Absenteeism
Dropout

Figure 9: Distribution of indirect costs of diabetes in sub-Saharan Africa (2015)
Data are authors’ estimates. Productivity losses consisted of four components:
premature mortality, reduced labour-force participation due to diabetes-related
complications and malaise (dropout), increased likelihood of taking sick leave
(absenteeism), and decreased productivity while working (presenteeism).

Prevalence ≤3%

Prevalence >3%
to ≤7·5%

Prevalence >7·5%

Low-income countries

0%/35%/70%

0%/20%/40%

0%/5%/10%

Middle-income countries

0%/50%/100%

0%/35%/70%

0%/17·5%/35%

High-income countries

0%/25%/50%

0%/10%/20%

0%/2·5%/5%

Data are the assumed growth in age-group-specific and sex-specific prevalence and mortality from 2015 to 2030 for
scenarios A/B/C, depending on 2015 adult prevalence and income classification. Data for 2015 come from the
International Diabetes Federation Diabetes Atlas.25 Growth rates for high-income countries with low or medium
diabetes prevalence are only provided for reference, since no country in sub-Saharan Africa fell into this category.

Table 9: Summary of scenarios for the evolution of age-group-specific and sex-specific prevalence and
mortality by income group and 2015 adult prevalence for countries in sub-Saharan Africa
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Figure 10: Projected
economic costs of diabetes
in sub-Saharan Africa
(2015–30)
Data are authors’ estimates.
(A) Absolute costs; dark
shades indicate direct costs.
(B) Costs as a percentage of
GDP. Scenario A assumes
constant age-group-specific
and sex-specific prevalence,
whereas scenarios B and C
allow growth rates to vary
with initial prevalence and
country-income level.
GDP=gross domestic product.
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Panel 7: Benefits of managing diabetes using a benefit-based tailored treatment or treat-to-target strategy in
sub-Saharan Africa
We constructed a microsimulation model, which simulates
individuals with diabetes by sampling from correlated
probability distributions describing the relationships between
demographics and risk factor values in the populations of
interest. Individual demographics included age and sex, with
population sizes taken from the UN Population Division’s
projections for 2015–25, and the subset of the population
expected to be born or already alive with diabetes during this
period based on International Diabetes Federation estimates
for diabetes prevalence and trends for the age group of 30–70
years.12 The microsimulation model (method published in
detail elsewhere152 and described in the appendix 1) enabled
us to compare the approaches to reducing the risk of major
macrovascular (myocardial infarction, stroke) and
microvascular (neuropathy, retinopathy, and end-stage renal
disease) complications of diabetes in two populations aged
30–70 years in sub-Saharan Africa: one from
Malawi (n=35 730), who are participants in the Karonga
Prevention Study,224 and the other from combined datasets
from Ghana and South Africa (n=3938 and 2352,
respectively), representing sub-Saharan Africa (see appendix 1
for methods).
The methods and limitations have been described in detail
elsewhere.152,223 Briefly, two alternative management
approaches were compared. The first was a treat-to-target
(TTT) strategy involving titration of blood pressure medication,
statins, and glucose-lowering drugs to predefined targets. Thus,
the TTT strategy involved treating individuals with blood
pressure medication until they achieved a blood pressure of less
than 130/80 mm Hg;225 with a statin until they achieved an LDL
concentration of less than 2·59 mmol/L (100 mg/dL);226 and
with metformin and sulfonylureas (and, if needed, substituting
the sulfonylurea with insulin) until they achieved an HbA1c level
of less than 7%.136,137
The second strategy was a benefit-based tailored treatment
(BTT) strategy, which involved treating individuals at high
risk of macrovascular complications with blood pressure

With the TTT strategy, the estimated total drug costs in
the countries studied would be US$1346·6 million
(95% CI $471·1–2206·7 million; 2016 prices) over the
simulated period of 10 years, whereas with the BTT
strategy, the estimated total drug costs would be higher at
$1407·9 million ($464·7–$2332·5 million). In terms of
total DALYs averted, the benefits of BTT were estimated
to be superior (table 10), with BTT saving 1·89 million
DALYs (0·89–3·38 million) and TTT saving 1·16 million
DALYs (0·55–2·07 million) in the simulated period of
10 years in sub-Saharan African countries. With BTT,
the mean costs per DALY averted were $743·4
($137·5–$2627·2) for the BTT strategy and $1159·5
($227·6–$4047·5) for the TTT strategy (table 10).

medication and statins, and those at high risk of
microvascular complications with glucose-lowering agents,
until they achieved low risk levels. Specifically, the BTT
strategy involved treating individuals with a
10-year combined risk (assessed using UKPDS outcomes
model 2—see appendix 1 for further details) of myocardial
infarction and stroke of more than 10% with antihypertensive
drugs and a statin until their risk was lowered to below the
10% threshold (provided blood pressure remained
>110/55 mm Hg for safety). Additionally, the strategy
involved treating those with a lifetime risk of the three major
microvascular complications (blindness, end-stage renal
disease, and amputation secondary to neuropathic ulcer) of
more than 4% with metformin and sulfonylureas (and, if
needed, substituting the sulfonylurea with insulin) until
lifetime microvascular risk was below 4% (provided fasting
blood glucose remained >3·33 mmol/L [60 mg/dL] for
safety).
We compared each method with the current situation in each
individual country and then compared the average
cost-eﬀectiveness ratios of the BTT and TTT strategies. We used
WHO guidelines227 to choose blood pressure and statin
medications and the Yale Diabetes Center Guidelines228 for
dose-escalation algorithms for metformin, sulfonylureas, and
insulin.
Cases averted, disability-adjusted life-years (DALYs) saved
(based on disability weight values estimated by the Global
Burden of Disease study229), and drug costs for therapy (based
on per-unit global buyer cost estimates from the International
Medical Products Price Guide192) were integrated over the
simulated lifecourse of all people with diabetes who were alive
or born during the next 10 years using the projected estimates
for the population and those with diabetes, as per standard
cost-effectiveness guidelines.230 Additional service delivery costs
were assumed to be the same for each strategy. DALYs and
costs were discounted at a 3% annual rate, the rate used by
WHO,231 and costs are expressed in 2016 US dollars.

These results show that there are potentially substantial
benefits for scaling up diabetes services to address unmet
need. The question remains as to whether countries will
be able to strengthen health systems to respond to those
needs.

Service delivery models for managing diabetes
in sub-Saharan Africa
Encouraging examples of successful models of diabetes
care are emerging in LICs and in sub-Saharan Africa. In
this section, we explore these models and provide countrycase examples of innovative approaches introduced in
sub-Saharan Africa to effectively manage diabetes to
show what might be possible in the future.
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Malawi (n=8 632 000 people aged 30–70 years,
about 604 000 with diabetes)

Sub-Saharan Africa (n=318 850 000 people aged
30–70 years, about 24 870 000 with diabetes)

TTT

BTT

TTT

BTT

522·0
(86·4% [85·4–87·4%])

534·1
(88·4% [87·4–90·0%])

23 942·7
(96·3% [95·2–97·3%])

21 688·3
(87·2% [65·6–100·0%])

Blood pressure treatment

300·9
(49·8% [40·0–59·6%])

490·6
(81·2% [72·4–90·0%])

13 800·9
(55·5% [44·6–66·4%])

19 922·6
(80·1% [54·3–100·0%])

Lipid treatment

478·6
(79·2% [62·6–95·8%])

490·6
(81·2% [72·4–90·0%])

20 420·1
(82·1%[67·4–100%])

19 922·6
(80·1% [54·3–100·0%])

Glycaemic treatment

300·3
(49·7% [47·9–51·5%])

313·8
(51·9% [50·0–53·8%])

12 814·1
(51·5% [51·5–52·7%])

13 387·9
(53·8% [53·8–55·0%])

3·6 (3·5–3·9)

4·3 (4·2–4·5)

Adults with diabetes recommended
treatment, thousands

Number of medications per person for
recommended treatment
Percentage of those on glycaemic
treatment requiring insulin

3·5 (3·2–3·8)
19·4% (17·4–21·4%)

4·5 (4·3–4·7)
20·3% (18·2–22·4%)

20·1% (18·7–21·9%)

21% (19·6–22·9%)

Macrovascular events prevented per 10 years, thousands
Myocardial infarction

2·4 (2·2–2·7)

9·6 (7·6–11·4)

108·9 (103·8–122·4)

226·2 (182·5–268·3)

Stroke

3·8 (3·5–4·2)

13·7 (11·5–15·8)

174·4 (163·0–189·1)

322·8 (276·0–371·3)

Microvascular events prevented per 10 years, thousands
Blindness

0·6 (0·2–2·4)

0·6 (0·1–2·3)

26·6 (8·7–105·4)

End-stage renal disease

0·6 (0·1–0·5)

0·6 (0·0–0·3)

26·6 (3·6–23·9)

25·9 (0·5–11·4)

Amputation

1·5 (0·2–2·7)

1·6 (0·3–4·2)

66·4 (10·7–118·8)

69·4 (11·5–182·8)

4·7 (0·5–10·2)

14·0 (1·6–31·7)

Deaths averted per 10 years, thousands

25·9 (5·5–95·9)

212·6 (25·7–454·2)

358·0 (40·4–833·7)

Number needed to treat to prevent
one macrovascular event per 10 years

83·9 (75·3–92·4)

23·0 (19·6–27·9)

84·5 (76·9–89·7)

39·5 (33·9–47·3)

Number needed to treat to prevent
one microvascular event per 10 years

193·2 (91·8–1042·9)

189·2 (78·6–1355·5)

200·3 (96·5–1041·9)

178·9 (74·8–1238·0)

Cost and cost-effectiveness
Total drug costs per 10 years,
thousand US$ (2016 values)
Total DALYs averted per 10 years,
thousands
$ per DALYs averted

31 443·3
(10 612·4–51 794·0)
25·8 (11·6–46·7)
1221 (227·3–4476·8)

33 577·7
(12 020·7–53 600·4)
73·2 (36·5–124·6)
459 (96·5–1466·9)

1 346 617·9
(471 138·5–2 206 655·0)

1 407 869·7
(464 664·0–2 332 519·3)

1161·3 (545·2–2070·2)

1893·9 (887·8–3380·4)

1159·5 (227·6–4047·5)

743·4 (137·5–2627·2)

Data are n (% [95% CI]) or n (95% CI). 95% CIs were estimated from 10 000 repeated simulations of the model in which the probability distributions of all input parameter
values were repeatedly sampled to identify uncertainty in the outcome metrics shown. Data to represent sub-Saharan African countries were drawn from cohorts from Ghana
and South Africa obtained from the WHO Study on Global Ageing and Adult Health.232 For more detail on methods, see panel 7 and appendix 1. BTT=benefit-tailored therapy.
TTT=treat-to-target strategy. DALY=disability-adjusted life-year.

Table 10: BTT versus TTT in a microsimulation model of treatment for people with diabetes in Malawi, and in sub-Saharan Africa generally

We reviewed published studies of existing approaches
to diabetes care in sub-Saharan Africa (see appendix 1
for methods). We also did case studies to examine
current practices in seven countries (Botswana,
Ethiopia, Kenya, Malawi, Mali, Rwanda, and South
Africa; see appendices 2–8 for details), using a
framework that has been used previously to analyse
different disease programmes233–237 in several settings238
and that was adapted for diabetes. Additionally, we
examined how existing and new technologies could be
harnessed to help improve management of diabetes in
sub-Saharan Africa.
Our literature review identified 467 studies, of which
32 from 11 different countries (Cameroon, Eritrea,
Ethiopia, Ghana, Kenya, Malawi, Mozambique, South
Africa, Sudan, Tanzania, and Uganda) met the inclusion
criteria (ie, if they described or evaluated a new or
previously existing model of diabetes care in sub652

Saharan Africa; appendix 1). The review showed that, in
many sub-Saharan African countries, diabetes care is
still mostly available only in the hospital setting,
requiring patients to travel great distances to access
services and follow-up care important for effective
diabetes management. However, several countries have
seen success with the introduction of new, decentralised
care-delivery models for management of diabetes (eg,
in primary health centre, community, or home settings),
with an emphasis on use of nurses and community
health workers, patient education, and community
engagement.
Cameroon and Tanzania have introduced communitybased management of diabetes.239 In Cameroon, facilitybased interventions for high blood pressure and diabetes,
involving task shifting and nurse-led care in rural health
districts, significantly improved patient retention in
cardiovascular disease management programmes.240
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Similarly, in Kenya, management of high blood pressure
and diabetes has been delegated to rural primary healthcare clinics, with good retention rates and control.241 In
Ethiopia, physicians and diabetes-trained nurses travel
from hospitals to rural medical centres for training and
care provision, with early encouraging results in
improving access to services.242,243
In the public sector in South Africa, a chronic disease
outreach programme, which used nurses in primary
health centres to provide educational and follow-up
advice to patients with diabetes, improved early detection
and referral of high-risk, poorly controlled patients to
specialist centres.244 Decentralisation of diabetes
management to the community level was also successful
in the private sector in South Africa, where the care of
diabetes was transferred to physicians working in
community-based primary health centres affiliated with
a diabetes and endocrinology centre. The scheme used
community-based capitation and a financial risk-sharing
model for diabetes and led to major reductions in
hospital admissions for both acute metabolic
emergencies and all causes, as well as reduced costs,
delayed progression of microvascular complications, and
improved outcomes.245
Nurse-led diabetes care, with a nurse-led protocol and
education-based system, was also shown to be successful
in rural KwaZulu-Natal in South Africa, with improved
control of HbA1c and increased satisfaction for patients,
their families, and health workers.246,247 Although the
improvements in glycaemic control achieved at 18 months
following the introduction of that scheme were not
sustained at 48 months, mean HbA1c concentrations at
48 months were lower than at baseline.247 Similar to South
Africa, the introduction of protocol-driven, nurse-led
management of diabetes in primary health-care centres in
rural and urban Cameroon also led to improvements in
glycaemic control and blood pressure.248 However, a
study249 of a community-health-worker model of outpatient
care introduced in South Africa for diabetes and
hypertension—which involved monthly home visits,
counselling services, and access to monthly supplies of
medication—showed improved control of hypertension
but not of diabetes, with 11 (26%) of 42 patients at the
clinic showing improved glycaemic control compared
with only two (9%) of 22 patients visited at home by
community health workers.
Combined with decentralisation of services, plans to
specifically integrate care have been successful. In
Cameroon, integration of care for high blood pressure
and diabetes was effectively achieved in eight rural health
districts by task shifting to health-care facilities with nonphysician clinicians, with improved control of risk factors
in patients attending those services.249
In South Africa, home glucose monitoring with urine
testing was introduced 30 years ago, including for
illiterate patients with diabetes, with good compliance
and lower random glucose levels in compliers than in

non-compliers.250 In Kenya, a home glucose monitoring
programme that used mobile phones to enable
community health workers to regularly communicate
with patients to modify the dose of insulin injections
helped to improve HbA1c concentrations.251,252
Patient education has also been used in several settings
to improve services across the care continuum and to
decentralise care away from hospitals to the patient level.
For example, in Cameroon, motivational counselling and
education were integrated into a screening programme to
improve rates of follow-up for patients newly diagnosed
with diabetes.253 In South Africa, group education was
used at community health centres to improve patients’
knowledge and management of diabetes, although no
improvements were seen in diabetes self-care activities,
weight loss, HbA1c concentrations, quality of life, selfefficacy, locus of control, blood pressure, waist
circumference, or total cholesterol levels.144 Another
study254 from South Africa showed that a group education
programme for patients with type 2 diabetes could be
implemented in rural areas with a dietitian or health
promoter to provide a supportive environment for
patients to learn and cope. That programme led to
significant improvements in adherence to a diabetesappropriate diet, physical activity, foot care, and the
perceived ability to educate others, although no significant
change was seen in smoking or adherence to medication.254
In Tanzania, a hospital-based education programme for
children with type 1 diabetes about symptom
management, correct insulin storage, and insulin
administration led to reductions in severe hypoglycaemia,
but no improvement in HbA1c concentrations.255 In
Mozambique, twinning programmes have been used to
successfully establish patient education programmes and
to improve their effectiveness.185
In addition to patient education, health-provider
education at hospitals and primary health-care centres,
and at the community level, has been used to improve
early recognition of diabetes and diabetic sequelae and to
enhance disease management in sub-Saharan Africa. In
Tanzania, where 70% of leg amputations occur in patients
with diabetes,109 training of health-care personnel at
different levels in diabetic foot management has led to
improved case finding, earlier referrals, establishment of
well functioning foot clinics, and strengthened
management of diabetic foot ulcers, with better health
outcomes.109 In Eritrea, a cooperative diabetes project that
emphasised multidisciplinary training of physicians,
laboratory scientists, diabetes nurse practitioners, patient
educators, and dietitians, and improved quality of
laboratory services, led to improved management of
diabetes, with better HbA1c concentrations.256 Multi
disciplinary training for diabetes, involving physicians,
dietitians, nurse educators, and pharmacists, has also
been introduced in Ghana to strengthen diabetes
services,257 while training of patient educators has been
introduced in Sudan.258
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In sub-Saharan Africa, electronic medical records,259
treatment protocols, and guidelines260 have facilitated the
development of primary care, community, and homebased service models. For example, Malawi has
successfully used existing service-delivery platforms and
expertise in tuberculosis management, which has well
established treatment guidelines and monitoring and
reporting mechanisms, to introduce chronic disease
management and reporting for diabetes.261
Integrating care of diabetes and hypertension into
existing chronic care models for HIV has also been
deemed a promising strategy. South Africa has used—in
urban and peri-urban townships of the metropolitan
region of Cape Town in Western Cape—mobile units for
HIV counselling and testing as an entry point for
combined screening of high blood pressure and diabetes,
with a high yield of new cases, although linkage to care
and follow-up was challenging.225 Community-based
HIV-testing campaigns were used in Uganda to
simultaneously offer diagnostic, preventive, treatment,
and referral services for HIV, malaria, tuberculosis, high
blood pressure, and diabetes, with effective linkage to
care.262 In a study done in Kenya,252 HIV counsellors were
trained to screen for diabetes and high blood pressure in
home-based screening, and district hospital-based staff
to do community-based screening; both approaches
showed effective uptake, although, in both, follow-up
levels were low, with only one-fifth of all patients screened
returning after a random glucose test.
Diabetes management in Africa is strongly reliant on
the non-physician health workforce, including nurses,
community health workers, and health extension
workers, as well as traditional healers in some settings.
Several countries, such as Botswana, Ghana, Ethiopia,
Kenya, Malawi, Mali, Rwanda, Tanzania, and South
Africa, have introduced innovative approaches to address
resource constraints when managing diabetes (see
panel 8 for a summary of initiatives for and barriers to
providing diabetes care in selected countries in subSaharan Africa). In-country case studies for Botswana,
Ethiopia, Kenya, Malawi, Mali, Rwanda, and South Africa
are published as appendices 2–8.

Harnessing new technologies to improve
diabetes care in sub-Saharan Africa

Improving access to existing technologies for better
diabetes care in sub-Saharan Africa
New technologies for diabetes care have been developed
for use in resource-rich health systems, but not for those
in sub-Saharan Africa. In the region, the necessary
technologies either do not exist (requiring the
development of low-cost health technologies), or
technologies exist but are not accessible because of high
costs, or accessible technologies are not adopted because
of health system barriers.
Most health technologies used to diagnose, monitor,
and treat diabetes and its complications are not
654

affordable for patients in sub-Saharan Africa. Patients
experience difficulties in accessing health centres and,
when they do, incur impoverishing expenditures.176,177,263–266
Increased availability of low-cost and accurate
diagnostics for point-of-care testing of blood glucose,
HbA1c, glycosuria, and proteinuria could improve
screening, diagnosis, treatment, and monitoring of
diabetes and help to mitigate access constraints in
delivering effective diabetes care, particularly when
combined with a distributive model of primary-healthcentre-based and community-based services provided
by community health workers (panel 8).
Ensuring timely and affordable access to existing costeffective technologies, such as appropriate forms of
insulin,267 medicines, miniaturised blood glucose
sensors, and strips for testing of urinary glucose or
protein, is a challenge in sub-Saharan Africa. Improved
technology assessment, procurement, and supply-chain
management can help to achieve greater value for money
and timely delivery of available medicines to avoid
treatment interruptions and expand access.268
Strategies for improved use of cost-effective technology
should emphasise both health technologies (eg, new
therapeutics, diagnostics, and medical devices) and
technologies for health (eg, communication and transport,
which affect health). These strategies should foster
investments in hard (infrastructure and equipment) and
soft (information and communication technology [ICT],
with data analytics as an example) technologies.
In sub-Saharan Africa, ICT has been used variously in
HIV and tuberculosis programmes,269 but, overall, its use
in health systems is low. Diabetes registries, which form
the mainstay of diabetes care platforms in HICs, are only
available in six (17%) of 35 countries that responded to
the WHO survey in the entire WHO African region.83
One possibility is to extend existing databases for HIV
and tuberculosis to include diabetes and NCDs. In
countries where no such systems exist, development of
future-proof diabetes registries should be prioritised.
The absence of legacy systems provides an opportunity to
introduce cost-effective ICT solutions that use mobile
telephones to facilitate data sharing.270–272 For example,
existing solutions using cloud technologies offer an
important opportunity to capture and integrate real-time
data across multiple mobile phones, point-of-care
devices, laboratory diagnostics, and electronic health
records (panel 9).

Improving adoption and dissemination of new health
technologies for diabetes care in sub-Saharan Africa
Factors that hinder adoption and dissemination of new
technologies in sub-Saharan Africa include imprecise
definition of the problem being addressed; complexity
and scalability of the technology or intervention;
resistance from the adoption system (eg, health
professionals and service users); characteristics of the
health system that create rigidities or provide inadequate
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Panel 8: Health services for diabetes in sub-Saharan Africa: a summary of the Commission’s case reports of seven countries
(see appendices 2–8 for more detail and references)
In Botswana, patients with diabetes have access to general
nursing, psychological, and social work services, both in the
private and public sectors. Community health workers and
diabetes youth leaders provide education and public health
screening campaigns.
In Ethiopia, diabetes services are delivered mainly at primary
health centres. Specialist clinics located in the major university
teaching hospitals also provide diabetes care by endocrinologists
or general internists. Nurses, health officers, and general
practitioners provide most of the diabetes care in health centres
and general hospitals. In 2014, an estimated six of ten health
facilities, excluding health posts, provided diabetes care,
although most patients with diabetes are undiagnosed.
After the launch of a national diabetes strategy in 2010, Kenya
began to expand diabetes services, with training of health-care
professionals and community health workers, development of
national guidelines, and provision of diabetes screening.
However, services at the level of the community and primary
health centre are hampered by the inconsistent availability of
drugs and diagnostic equipment.
Malawi has low numbers of health personnel and resource
shortages, and patients with diabetes are underdiagnosed and
poorly controlled. However, Malawi is piloting the WHO Package
of Essential Noncommunicable Disease Interventions for
Primary Health Care in Low-Resource Settings and set a target
to give 1000 health workers specialist training by 2016. Malawi
has introduced new service-delivery models for diabetes that
mimic the directly observed treatment (short-course) approach
used in tuberculosis care and home-based care and peer support
used in management of HIV.
Rwanda is introducing clinical non-communicable disease
(NCD) services and care packages across all health facilities
and an NCD clinic model in district hospitals and health

incentives; and poor recognition of the challenge of
diabetes in the broader context (among the population
and politicians), such that it is not considered an urgent
and major societal challenge.281,282
As we have discussed, emerging care-delivery models
for diabetes in sub-Saharan Africa have distinctive
features: a public health approach, with simplification
and decentralisation of care to primary health centres
and communities and with strong reliance on a nonphysician health workforce (including nurses,
community health workers, and health extension
workers); community involvement; peer support; and
self-management. Expanded access to existing tech
nologies can help sub-Saharan Africa not to replicate
western models of care, which often favour an expert-led
approach, but to foster innovative delivery models that
reflect the African context and to build on experience of
the innovations in care delivery with HIV/AIDS.283,284

centres. The number of people living with diabetes and
requiring close follow-up has increased. To address the
shortage of health professionals and increasing demand for
health care, Rwanda has introduced pre-service and in-service
training for existing staff in the management of NCDs, started
a programme of task shifting to transition chronic disease
management to the home setting, and created a new cadre of
health professionals (home-based care practitioners) at the
community level to provide home-based services for diabetes
and other NCDs.
In 2011, Tanzania established a National Diabetes Program as a
collaboration between the Ministry of Health and Social Welfare
and the Tanzania Diabetes Association—the implementing
agency for the programme—that has used existing government
facilities and staff to establish 148 diabetes clinics in zonal,
regional, and district hospitals. Using funding from
international agencies and the private sector, Tanzania’s
National Diabetes Program provides funding for equipment
and training of personnel to provide care for around
800 000 people with diabetes. Diabetes care is provided free of
charge to patients, and the government mandates that
diabetes drugs should be given free of charge to patients using
district and regional diabetes clinics.
In South Africa, diabetes care is provided in the public and private
sectors, but huge inequities exist: the public sector provides for
84% of the population and spends US$140 per person each year
(4·2% of gross domestic product [GDP]), whereas the private
sector provides for 16% of the population and spends $1400 per
person each year (4·3% of GDP). A network of national health
laboratories provides services to more than 80% of the
population for all standard diabetes-related investigations, but
not all primary health clinics have access to standard diagnostic
equipment because of budgetary constraints.

Creating a successful response to diabetes in
sub-Saharan Africa
Aligning with global targets

Health systems in sub-Saharan Africa are unprepared for
the rapidly increasing burden of diabetes. Consequently,
many people go undiagnosed, and those who are
diagnosed are not screened for comorbidities, do not
receive treatment, or are not adequately controlled. The
resultant morbidity and mortality lead to immense
human, economic, and societal losses.
The increasing prevalence of diabetes in sub-Saharan
Africa reflects not just greater numbers of people with
the disease, but also a changing phenotype. The approach
to managing such a complex and heterogeneous disorder
has to be multisectoral, with education, engagement, and
cooperation of individuals, and with awareness and
education of the community. Specific therapeutic
measures are not enough; successful management of
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For more on SDG 3 see
http://www.un.org/
sustainabledevelopment/health

diabetes in sub-Saharan Africa requires an enabling
medical, social, and political context within which
effective prevention, screening, diagnosis, treatment,
and lifelong care can be delivered. In this respect, lessons
can be learned from the HIV response in Africa, which
successfully brought together governments, civil society,
health-care providers, communities, donors, and the
private sector.
The burden of diabetes in sub-Saharan Africa and its
impact on individuals, populations, health systems,
and economies means that policy makers must act to
bring together wide-ranging stakeholders to spur action
at country and global levels around a set of ambitious
yet achievable targets, linked to those set in SDG 3:

“ensure healthy lives and promote well-being for all at
all ages”. Of the 13 targets set for SDG 3, six are most
readily applicable to diabetes in sub-Saharan Africa:
(1) by 2030, reduce by one-third premature mortality
from NCDs through prevention and treatment;
(2) achieve universal health coverage, including
financial risk protection, access to quality essential
health-care services and access to safe, effective, quality,
and affordable essential medicines and vaccines for all;
(3) strengthen the implementation of the WHO
Framework Convention on Tobacco Control in all
countries, as appropriate; (4) support the research and
development of vaccines and medicines for the
communicable diseases and NCDs that primarily affect

Panel 9: Possibilities for affordable, cost-effective technologies for diabetes care in sub-Saharan Africa
For more on the Portable Eye
Examination Kit see
http://www.peekvision.org
For more on epiCam see
http://www.epipole.com/epicam

For more on SUDOSCAN see
http://www.sudoscan.com
For moreon NC-stat DPNCheck
see http://www.dpncheck.com

Technologies to support diabetes diagnosis and
management
Low-cost diagnostic devices that enable point-of-care testing
of blood glucose, HbA1c, glycosuria, and proteinuria could be
used for screening, diagnosis, treatment initiation, and
monitoring. Yet, although low-cost, affordable devices do
exist, such devices are produced by numerous manufacturers
and often little compatibility exists between the necessary
elements of the equipment (eg, blood glucose sticks) needed
to use such devices, even for some manufacturers’ own
models. Encouraging diagnostic device manufacturers to make
changes towards greater interoperability will necessitate a
more centralised approach to procurement of diagnostic
devices used in the management of non-communicable
diseases (NCDs). Moreover, international bodies such as WHO
have an important part to play in developing the technical
standards required for improved integrated diagnostic
infrastructures for NCDs such as diabetes, just as these bodies
did in strengthening diagnostic service infrastructures for
infectious diseases such as HIV and tuberculosis. Improved
interoperability of developed technologies that have
interchangeable disposable components is needed to ensure
that low-cost models can be used in low-income and middleincome countries.
Results from such devices could be used in combination with
mobile phones or smartphones to target messaging for
preventive interventions,273 to communicate test results to
patients,274 or to self-monitor diabetes (to help to improve
adherence).275 Affordable diagnostic and communication
technologies could help to transform diabetes care, as they
have done for HIV management in resource-poor settings.276,277
Technologies to support screening for diabetes
complications
Effective early detection of diabetic retinopathy, which might
reduce the risk of blindness by 95%, currently requires both
clinical staff with ophthalmological training and costly
equipment to carry out eye examinations. Both requirements
are a major obstacle to care, as shown by the case of Malawi,
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which has 17·8 million inhabitants but just nine
ophthalmologists.278 New devices, such as the Portable Eye
Examination Kit, which uses a smartphone, and the hand-held
epiCam device, which captures images digitally for
store-and-forward using a laptop computer, offer the possibility
of screening for diabetic retinopathy by health workers in
primary health centres, community-based services, and remote
rural areas. Although these devices rely on expert analysis for
interpretation of fundus images, diagnostic algorithms could be
used to remotely analyse and grade images at low cost. For
example, automated grading of fundus photographs is done
within established services, including the Scottish National
Diabetic Retinopathy Screening Programme, and has been
studied in Nakuru, Kenya.279 However, reliable supporting
infrastructure needs to be in place to allow the widescale
adoption of such technology.
Peripheral neuropathy is another important complication of
diabetes that has an urgent need for new diagnostic tools for
early detection; the prognosis of diabetic peripheral neuropathy
is poor if not diagnosed early. However, accurate diagnosis of
diabetic peripheral neuropathy represents a major challenge,
even in the context of resource-rich health systems.280 The
development and adoption of new non-invasive diagnostic
devices that enable point-of-care testing and do not require
specialised training to use—eg, SUDOSCAN and
NC-stat DPNCheck—could improve screening and early detection
of diabetic peripheral neuropathy in resource-poor settings.
Technologies to support diabetes surveillance
Cloud-based systems offer the possibility of capturing data
from multiple sources and devices in real-time and integrating
them. Data cloud solutions are low cost and more scalable than
traditional data storage systems (which are reliant on hardware
requiring constant electricity supply and regular servicing).
By integrating data from multiple devices and sources, cloud
solutions can help to manage the complex data needed for
management of diabetes across multiple facilities and over long
periods of time, and help to improve understanding of the
epidemiology of diabetes and responses to interventions.
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developing countries, and provide access to affordable
essential medicines and vaccines; (5) substantially
increase health financing and the recruitment,
development, training, and retention of the health
workforce in LICs, especially in the least developed
countries; and (6) strengthen the capacity of all
countries, in particular developing countries, for early
warning, risk reduction, and management of national
and global health risks (not just for infectious diseases,
but also for diabetes and other NCDs).
Additionally, countries in sub-Saharan Africa should
embrace the nine voluntary targets adopted at the
65th World Health Assembly by member states as part
of the WHO Global Action Plan for the Prevention and
Control of NCDs 2013–20: to reduce premature
mortality due to NCDs by 25%, to reduce physical
inactivity by 10%, to reduce tobacco consumption
by 30%, to achieve a 25% reduction in high blood
pressure, to achieve 80% coverage of essential
medicines and technologies for NCDs, and to achieve
0% increase in the prevalence of obesity and diabetes
by the year 2025.187 A Global Monitoring Framework
underpins the Global Action Plan, with 25 indicators
that are monitored by member states, of which 12 are
relevant to diabetes and can be used to monitor
achievements in sub-Saharan Africa.285
Achieving the targets set in SDG 3 and the Global
Action Plan would undoubtedly help to transform the
fight against diabetes in sub-Saharan Africa; avert
needless suffering and death; and reduce the economic
burden of diabetes on individuals, households, and
societies. The crucial components of an effective
response are solidarity and collective action at local,
national, African, and global levels, with clear
responsibilities for stakeholders as part of a collective
response. The chief elements of this response, on which
the Commissioners are in full agreement, are laid out
below. We have also described operational targets that are
achievable by 2020, 2025, and 2030 in panel 1.

Role of governments
Ultimately, governments should respond to the needs of
their populations. In addition to enabling access to health
services, governments should consider introducing
public health measures to reduce NCDs, including
banning smoking in public places, restricting advertising
of unhealthy foods and beverages, creating or increasing
taxes on cigarettes and sugar-sweetened beverages, and
limiting portion sizes of sugar-sweetened beverages.43,286
A health-literate population is crucial for generating
demand for health interventions, improving access to
health systems, and ensuring uptake of preventive
measures. Much health literacy in sub-Saharan Africa has
come from successful media campaigns via radio and
poster adverts and education through interaction with
community health workers. These campaigns have
generally focused on prevention of HIV (eg, condom use)

and malaria (eg, use of insecticide-treated bednets),287 and
have led to increased use of preventive interventions.
Investment and research is now needed to build on these
initiatives and to increase population awareness of
diabetes and generate health-care demand for diabetes
and NCDs. Therefore, we recommend that countries in
sub-Saharan Africa research and develop locally
appropriate media campaigns to educate the public about
the symptoms of type 1 and type 2 diabetes and encourage
those with symptoms to seek care. In particular, media
campaigns should be deployed to educate citizens about
preventive lifestyle measures, combined with government
regulations that restrict advertisements for unhealthy
foods.
We also recommend that governments should allocate
sustainable funding to tackle the diabetes epidemic. As
noted earlier, we have estimated that, in 2015, the
economic burden of diabetes in sub-Saharan Africa was
US$19·45 billion, or 1·2% of cumulative GDP of the
whole sub-Saharan African region. Unchecked, this
economic burden is projected to increase to between
$35·33 billion and $59·32 billion by 2030 (figure 10).
Given the strong causal link between NCDs (including
type 2 diabetes), sugar-sweetened beverages, salt, and
tobacco, we strongly advise countries to consider raising
revenues by taxing these products to fund health systems.
Although all too often considered a disease of the rich,
the burden of type 2 diabetes in sub-Saharan Africa is
increasingly borne by the poor.21 Making available and
encouraging healthy choices, and taxing unhealthy
choices, should help to promote the health of the poorer
sectors of society, while increasing revenue for treasuries
to finance health systems and expand access to effective
health care.
Such taxes should be combined with assessments of
national health systems and actions to establish effective
and efficient responses to the burden of diabetes to
further expand fiscal space. Assessments should detail
the burden of diabetes and its comorbidities, and their
management at all levels of the health system, and
involve analyses of the capability of human resources,
the availability and costs (to individuals and health
systems) of drugs and equipment, the functioning of
supply-chain management, and how the services and
platforms developed for communicable diseases can best
be leveraged to also provide services for diabetes. In line
with this recommendation, governments should
prioritise data collection for the improvement of
population health. Integrated digital health information
systems are urgently needed to capture data about
diabetes, its comorbidities, and their management in
health systems, with timely analysis to inform planning
and improve care.
Diabetes can be treated cost-effectively and its
sequelae prevented if the disease is promptly diagnosed.
The medicines required are on the WHO 2015 essential
medicines list and are off-patent and affordable.
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Additionally, angiotensin-converting enzyme inhibitors
for protection against microvascular disease should be
made widely available (indeed, enalapril is currently
included in the WHO list of essential medicines, albeit
as an antihypertensive).288 Unlike other essential
medicines used for diabetes management, generic
forms of insulin are generally not widely available.
However, countries can purchase vials of human insulin
at prices similar in cost per person each year to that paid
for a 1 year supply of fixed-combination antiretroviral
treatment. Given the absolute need for insulin treatment
for type 1 diabetes, and the increasing need for insulin
to treat type 2 diabetes, human insulin should be widely
available for all those who need it. We believe that, in
the context of LICs in sub-Saharan Africa, more
expensive analogue insulins do not provide enough
extra benefit to justify their current costs.149 Considering
treatment, we urge countries to make available all
necessary medicines for diabetes, hypertension, and
cardiovascular disease on the WHO essential medicine
list at no cost to all patients who need them. Although
newer treatments for type 2 diabetes might have some
benefit over standard oral antihyperglycaemic agents
and insulin, these treatments could be considered a
worthwhile investment for the public sector only once
the countries have been able to provide essential
services and medicines for diabetes (table 1).
Human resource shortage is a crucial challenge, and
there is an urgent need to educate and train all groups
of health professionals—ranging from community
health workers to specialist physicians—in the
management of diabetes at all stages of the care
continuum to enable increased detection and improved
treatment. The need for training is especially great in
areas where there is already substantial contact with the
health system—for example, in children so that
diagnosis of type 1 diabetes is not missed, with fatal
consequences; in areas of maternal health, to ensure
diagnosis and treatment of gestational diabetes
(panel 4); and in communicable diseases, to ensure
effective management of interactions between diabetes
and communicable diseases. Once recognised,
diabetes—especially type 2 diabetes—can be effectively
managed. It is generally more cost-effective to train
existing staff to diagnose and treat diabetes than to
invest in highly trained specialists.
The sequelae of diabetes are insidious and present late
in the disease course. Their effective management
requires yearly monitoring at well equipped health
centres with health-care professionals able to manage
glycaemia and other cardiovascular risk factors and
screen for complications to improve macrovascular and
microvascular outcomes. It is essential that adequate
referral pathways are in place to ensure regular
monitoring and management of complications.
To minimise out-of-pocket costs from attending
multiple clinics, services for diabetes, other cardiovascular
658

risk factors, and chronic complications should be
integrated wherever possible.
Overall, governments should work towards Target 3.8
included in the SDGs: “achieve universal health coverage,
including financial risk protection, access to quality
essential health-care services and access to safe, effective,
quality and affordable essential medicines and vaccines
for all”.

Role of civil society
Civil society has a crucial role in catalysing change to
improve access to health care and in holding governments
to account. Advocacy from civil society was instrumental in
the global movement for HIV, which prompted the
convening of a special session of the UN General Assembly
in 2001 and led to the first UN declaration focusing on a
disease.289 Civil society could frame diabetes as an integral
part of the global commitments to addressing NCDs and
achieving universal health coverage, given links between
diabetes and so many other risk factors and conditions,
and use this narrative to build awareness and mobilise
support among a broad range of stakeholders.
Effective deployment of civil society requires
strengthening and expansion of networks and improved
modes of communication. In many countries in subSaharan Africa, diabetes organisations have an important
role in educating the public, health-care providers, and
governments about diabetes (see in-country case studies
in appendices 2–8). We recommend that diabetes
organisations should continue to promote the
improvement in management of diabetes across subSaharan Africa by tracking progress towards objectives set
out in national NCD or diabetes plans, and by holding
governments to account for their implementation.
However, funding is needed to ensure sustained
engagement of civil society. We urge donors and diabetes
organisations in other world regions to consider funding
or partnering with foundations in sub-Saharan Africa to
enable mutual learning, strengthen the agenda for
change, and ensure sustainability. Global NCD advocacy
organisations—for example, the IDF, NCD Alliance, and
World Heart Federation—have a key role in supporting
local organisations in sub-Saharan Africa.
Although not known for certain, it is feared that many
people with type 1 diabetes die undiagnosed or through
lack of access to treatment. Civil society should be
involved in raising awareness of type 1 diabetes and
should ensure that government guarantee a supply of
insulin to all patients, not just children.

Role of international donors
Although NCDs were identified as a priority in the 2011
UN High-Level Commission,290 with renewed
commitment in SDG 3, they still do not feature
prominently on the agendas of most global health
funders.14 To date, few donor agencies have provided
assistance for NCDs or for diabetes specifically.
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We do not know whether obesity and diabetes have
received so little attention because they are seen as
problems of lifestyle rather than of health, or because
infectious disease is seen as a greater menace.
Alternatively, NCDs might be less easy for international
donors to market to their supporters as worthy areas for
investment. Yet, evidence strongly suggests that
overweight, obesity, and diabetes are affected more by
environment than individual factors.291 Investment in
management of NCDs is imperative if the health gains
achieved in many countries in sub-Saharan Africa during
the Millennium Development Goal period (2000–15)—
because of improvements in maternal, neonatal, and
child health, and communicable diseases in that region—
are to be sustained. Hence, donors should increasingly
invest in evidence-based policies and health-systemswide strategies to address NCDs, communicable
diseases, and maternal and child health.

Role of global agencies
As with international donors, global agencies have been
slow to transition to a new world in which NCDs
predominate. The 2011 UN High-Level Meeting on
NCDs15,290 produced the UN General Assembly
Resolution292 committing UN member states to the
prevention and control of NCDs. In 2013, at the
65th World Health Assembly, member states agreed to
the aim of reducing premature mortality from NCDs by
25% by the year 2025, relative to 2010 levels.293 However,
in relation to action, apathy prevails;294 although a global
coordination mechanism, a monitoring framework, an
action plan, and a UN interagency task force have been
established, their benefits to those living with NCDs is
not sufficiently clear, given that targets are supposed to
be met in 2025 (in only 8 years).
WHO needs to be engaged in the production of
straightforward guidelines for countries looking to
improve NCD prevention, diagnosis, and care. For
example, lists of essential diagnostics for NCDs (akin to
the WHO essential medicines list) could be very
valuable.
WHO is well respected in sub-Saharan Africa and is
well placed to have a leadership role. WHO also has the
legitimacy to work with member states, other
international agencies, and civil society organisations to
mount an urgent and coordinated response to diabetes.
However, this opportunity can only be realised if WHO
acts on criticisms295 and lessons from the Ebola crisis to
emerge as a leader in the battle against diabetes and
NCDs. In addition to leading the response in countries,
an under-resourced WHO should follow a collegial route,
more widely involving external collaborators in efforts to
support the diabetes response.24
The World Bank, with its development capability; the
Global Fund, with its financing prowess; UNITAID, with
expertise in innovative financing and creation of market
dynamics to expand access to health technologies and

medicines; Gavi, in effective partnerships to expand
access to vaccines; the US Agency for International
Development, in reproductive, maternal, and child
health; and UNICEF, in building effective platforms for
managing childrens’ problems, could work together to
catalyse an integrated response to NCDs.
To date, most non-governmental organisations (NGOs)
in international health have focused on maternal,
neonatal, and child health; on communicable diseases;
and on providing health care in conflict settings.
Although some NGOs, such as the IDF’s Life for a Child
programme and Santé Diabète, have focused on diabetes,
these are exceptions. Encouragingly, Médecins Sans
Frontières is increasing its involvement in NCDs.296
We encourage NGOs working in sub-Saharan Africa to
recognise the importance of diabetes and obesity in the
populations they care for and, when possible, work in
concert with country health systems to find solutions to
improve diabetes care. This recognition is particularly
important for NGOs involved in communicable diseases
and in improving maternal and neonatal health, wherein
diabetes affects outcomes.

For more on the Life for a Child
programme see http://www.idf.
org/lifeforachild
For Santé Diabète see
http://www.santediabete.org/en
For more on Médecins Sans
Frontières see http://www.msf.
org

Research, development, and innovation
A global response to diabetes would not be possible
without effective research and development and an
innovation agenda to strengthen health systems, develop
affordable technologies and medicines, and find
innovative financing and service-delivery solutions.282,297
Throughout this report, we have highlighted the scarcity
of evidence needed to inform an appropriate broadbased health system response to deal with diabetes, its
complications, and other cardiovascular risk factors in
sub-Saharan Africa. This deficit in knowledge is seen at
all levels, from determining which measures to use to
define diabetes, to defining the burden of disease, to
making treatment decisions, and to planning costeffective health system development. Although some
studies have been done in the region, those studies have
often been small, out of date, or of poor quality. Our
concern is that many of those studies have been
assimilated into larger analyses and reports and thus
will become instrumental in defining a response to
diabetes in sub-Saharan Africa that might be wholly
inappropriate to needs. There is a crucial need for highquality studies done in sub-Saharan Africa that are
geared towards ensuring an effective health systems
response. To date, funding of studies of diabetes and
other NCDs in LMICs, including those in sub-Saharan
Africa, has been woefully inadequate. However, given
the urgency of the situation, we cannot advocate waiting
to implement strategies for NCDs and diabetes until
after the results of well done research studies have been
reported. We do, however, strongly urge that all strategies
are implemented in sub-Saharan Africa with
implementation science methodology and are done on
the background of a firm knowledge of baseline needs
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(including an accurate, population-level assessment of
disease burden). We also believe that no programme of
health care will truly maximise its potential unless there
is local ownership—this necessitates co-development of
research and implementation programmes with local
users and providers.298
The shortage of health professionals is a major barrier to
expansion of services in sub-Saharan Africa. Given
resource constraints, rapid expansion in numbers of
health professionals in the near future is not realistic.
Hence, addressing human resource shortages will require
a combination of strategies. The first of these strategies is
task-shifting or task-sharing, which has been effectively
implemented in sub-Saharan Africa to engage a broader
group of health professionals in diabetes care (see earlier
section on service delivery models for diabetes). The
second strategy is to leverage novel technology advances in
communications, including distance learning and
e-learning, through use of online courses to improve the
knowledge and competence of the existing health
workforce.299 The third strategy, among others, is to use
mobile technologies and SMS text messaging to improve
management of communications and processes in health
systems—for example, in communicating results,274
attending clinic appointments,276 and scaling up public
health and prevention interventions.273 In addition to
freeing up health-care-worker time, these measures also
improve patient self-management of long-term illnesses.300
Innovative opportunities also exist for increasing
financing resources. Financing initiatives such as the
airline solidarity levy and Debt2Health, which have been
used successfully for AIDS, tuberculosis, malaria, and
children’s immunisation programmes, offer possibilities
for funding of health systems and diabetes care,301,302 as
well as research.303

Conclusion
With rapid socioeconomic transitions occurring in subSaharan Africa, there is a risk that the increasing
prevalence of diabetes (and associated NCDs) will
overwhelm already struggling health services and have
adverse consequences for individuals and economies.
This Commission therefore chose to focus on this region
as a priority, although our findings could be translated to
other world regions facing similar challenges.
Our methods consisted of extensive reviews of the
literature; soliciting of expert opinion; performance of
primary research studies; and convening of
Commissioners’ meetings to discuss findings,
challenges, and solutions. The major limitation that
runs throughout all elements of the Commission is the
scarcity of reliable data to inform findings. However, the
findings presented here are robust to the current state of
knowledge in the region, and this Commission should
therefore serve as important reading for all members of
the health-care community (from health-care workers, to
ministers of health, and to heads of global development
660

agencies) whose aim is to improve care for people with
diabetes in sub-Saharan Africa. The finding of a paucity
of reliable data is also a key message of the Commission,
and more needs to be done to address the dearth of data
in the region.
We conclude that sub-Saharan Africa is not prepared
for the increasing burden of diabetes brought about by
rapid and ongoing transitions. Effective management of
diabetes in sub-Saharan Africa will require careful
considerations about the expansion of services to meet
current and future burden, while ensuring that services
are integrated with those for other chronic diseases. The
health, economic, and societal consequences of inaction
will be huge. Decisive action is needed now, by all
stakeholders, to address the scale and urgency of diabetes
in sub-Saharan Africa.
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